Infectious Diseases

IFN-γ +874 A>T (rs2430561) gene polymorphism and risk of pulmonary tuberculosis: a meta-analysis

Mohammed Y. Areeshi¹, Raju K. Mandal¹, Sajad A. Dar^{1,2}, Arshad Jawed¹, Mohd Wahid¹, Mohtashim Lohani³, Aditya K. Panda⁴, B.N. Mishra⁵, Naseem Akhter⁶, Shafiul Haque¹

¹Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan, Saudi Arabia

²The University College of Medical Sciences and GTB Hospital (University of Delhi), Delhi, India

³Department of Emergency Medical Services, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia

Centre for Life Sciences, Central University of Jharkhand, Ranchi, Jharkhand, India Department of Biotechnology, Institute of Engineering and Technology, Lucknow, Uttar Pradesh, India

⁶Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Albaha University, Albaha, Saudi Arabia

Submitted: 8 March 2017 Accepted: 15 October 2017

Arch Med Sci 2021; 17 (1): 177–188 DOI: https://doi.org/10.5114/aoms.2019.88481 Copyright © 2019 Termedia & Banach

Abstract

Introduction: The role of interferon gamma (IFN- γ) +874 A>T (rs2430561) gene polymorphism has been evaluated in different ethnicities with pulmonary tuberculosis (PTB) infection, and inconsistent results have been reported. In this study, a meta-analysis was performed to determine the precise association between IFN- γ +874 A>T gene polymorphism and PTB susceptibility. **Material and methods:** A total of 21 studies comprising 4281 confirmed PTB cases and 5186 healthy controls were included in this meta-analysis by searching the PubMed (Medline), EMBASE, and Google Scholar web-databases.

Results: We observed reduced risk of PTB in allelic contrast (T vs. A: p = 0.001; OR = 0.818, 95% CI: 0.723–0.926), homozygous (TT vs. AA: p = 0.017; OR = 0.715, 95% CI: 0.543–0.941), heterozygous (AT vs. AA: p = 0.002; OR = 0.782, 95% CI: 0.667–0.917), dominant (TT+AT vs. AA: p = 0.002; OR = 0.768, 95% CI: 0.652–0.906), and recessive (TT vs. AA+AT: p = 0.042; OR = 0.802, 95% CI: 0.649–0.992) genetic models. In ethnicity-wise subgroup analysis, reduced risk of PTB was found in the Caucasian population. However, we did not find an association with any of the genetic models in the Asian population.

Conclusions: In conclusion, the IFN- γ +874 A>T gene polymorphism is significantly associated with reduced risk of PTB, showing a protective effect in the overall and in the Caucasian population. However, this polymorphism is not associated with PTB risk in the Asian population.

Key words: meta-analysis, interferon-γ, pulmonary tuberculosis, polymorphism, genetic model.

Corresponding author:

Dr. Shafiul Haque Research and Scientific Studies Unit College of Nursing and Allied Health Sciences Jazan University Jazan-45142, Saudi Arabia Phone/fax: +966-173174383 E-mail: shafiul.haque@hotmail.com



Introduction

Tuberculosis (TB) is chronic infectious disease caused by *Mycobacterium tuberculosis* (*M. tuberculosis*). This is a disease of the lungs, mostly seen in the form of pulmonary type tuberculosis (PTB), which can easily be spread to others by coughing and breathing. Despite the availability of various effective treatment strategies, recent figures from 2014 show that TB is once more on the increase; globally, there is a large burden of the disease with ~9.6 million new cases and ~1.5 million reported deaths [1].

Nearly one-third of the world's population is thought to be affected with M. tuberculosis, but a large proportion of the population have no clinical symptoms of the disease. However, the remaining 5-15% of the population is affected with the active disease, as demonstrated by culturable bacilli from the sputum and other clinical symptoms [2]. This indicates that besides the mycobacteria itself, the host genetic factors may also determine the differences in host susceptibility to TB [3]. Earlier reports involving candidate gene approach and genetic association studies have identified various host genetic factors that affect the susceptibility in a variety of diseases [4–6]. So, the identification of host genes and genetic variations that play significant role in susceptibility and resistance to TB would help in understanding the pathogenesis of the disease and perhaps lead to new approaches of treatment or prophylaxis.

Cytokines, and their genes and receptors, have been implicated in the protective immunity, and also associated with pathological severity with altered circulating levels of pro-inflammatory and down-regulatory cytokines in TB [7]. In general, TB infects mainly macrophages in lungs, and Th1mediated immunity is considered as protective response against M. tuberculosis. The human interferon γ gene (*IFN* γ) is located on chromosome 12 (12q14) and has four exons spanning about 6 kb. Interferon γ (IFN- γ) encoded by *IFN*- γ (also called IFNG) is a key T helper (type-1) cytokine produced by natural killer (NK) cells and T cells. The production of IFN- γ is essential in innate immunity and plays a pivotal role in macrophage activation for eliminating Mycobacterium infection [8]. A previous study reported that malfunction of the *IFN-γ* gene may lead to infection of *M. tubercu*losis [9]. Single nucleotide polymorphisms (SNPs) present in the promoter or coding regions of cytokine genes result in altered transcriptional function and differential cytokine secretion. Also, the inter-individual variations in IFN- γ production are genetically contributed by polymorphisms within the promoter or coding region.

An SNP located in the +874 A>T (rs2430561) position in the first intron of the IFN- γ gene comprises the binding site for the transcription factor NF κ B, which putatively influences the gene expression and secretion of the cytokine, which has a significant impact on infection outcome. It has been reported that TB patients with the homozygous allele A combination produce significantly lower level of IFN- γ in comparison to individuals carrying one or two copies of allele T [10]. This polymorphism also displays variable associations with TB disease susceptibility and severity [11]. These studies demonstrated the importance of these cytokines in the development of TB infection and suggested that this genetic variant of the *IFN-\gamma* gene could account for the differences in TB susceptibility.

After considering the functional significance of this genetic variant, a number of case-control studies in recent years have assessed the association of *IFN-* γ +874 A>T gene polymorphism with PTB development in different populations. Results from these studies have shown mixed findings, and it is still unclear whether this polymorphism is associated with increased or decreased susceptibility to PTB [10, 12-32]. A probable reason to clarify the noted inconsistencies in the outcomes is the inadequate statistical power of the individual studies in which non-homogenous populations and individuals from different ethnicities were included. To overcome this situation, nowadays a meta-analysis statistical tool is used to explore the risk factors associated with the genetic diseases, as it employs a quantitative method of combining the data drawn from individual studies where sample sizes are too small to produce reliable conclusions [33]. Therefore, we carried out this meta-analysis to assess the effect of $IFN-\gamma$ +874 A>T gene polymorphism on the risk of PTB infection.

Material and methods

Strategy for literature search

Online web-databases, i.e. PubMed, Medline, EMBASE, and Google Scholar online, were searched for published research articles covering a combination of the following key words: *IFN-* γ , *IFN* γ gene, *IFNG*, interferon gamma gene (polymorphism OR mutation OR variant) AND tuberculosis susceptibility or TB or pulmonary tuberculosis or PTB (last updated on January 2017). We identified the potentially relevant genetic association studies by reading their titles and abstracts, and procured the most pertinent publications matching the preeligible criteria for a closer examination. In addition to the above-mentioned online database search, the references given in the selected research arti-

cles were also scrutinised for other potential articles that may have been missed in the preliminary search.

Criteria for inclusion and exclusion of the studies

In order to reduce heterogeneity and facilitate the apt interpretation of this pooled analysis, the published articles included in the present metaanalysis had to cover all the given criteria, as follows: a) they had to have reported case-control studies between *IFN-* γ +874 A>T gene polymorphism and PTB risk, b) they had to include clearly described confirmed PTB patients and PTB-free controls, d) they had to have available genotype frequency in both the cases and the controls, e) they had to be published in the English language, and f) the data collection and the analysis method had to be acceptable from a statistical point of view. Additionally, when the case-control study was involved in more than one research article using the same case series, we selected the research study that included the largest number of individuals. The major criteria for study exclusion were: a) overlapping or duplicate publication, b) the study-design based on only PTB cases, c) genotype frequency not reported, and d) data from review articles or abstracts.

Data extraction

For each retrieved research publication, the methodological quality evaluation and data extraction were independently abstracted in duplicate by two independent investigators (MYA and RKM) using a standard process. Standard datacollection form was used to endorse the precision of the collected data from individual studies by stringently following the pre-set inclusion criteria as mentioned above. The main characteristics abstracted from the retrieved publications comprised the name of the first author, the year of publication, the country of origin, the source of cases and controls, the number of cases and controls, the study type, and the genotype frequencies. Cases related with disagreement/discrepancy on any item of the data from the selected studies were fully deliberated with the investigators to reach a final unanimous agreement. In case failure to reach a consensus between the two investigators, a mutual agreement was attained with an open discussion with the adjudicator (SH).

Quality assessment of the selected studies

Methodological quality evaluation of the selected studies was performed independently by two investigators (MYA and RKM) by following the Newcastle-Ottawa Scale (NOS) of quality assessment [34]. The NOS quality assessment criteria included three major aspects: (i) subject selection: 0–4 stars, (ii) comparability of subject: 0–2 stars, and (iii) clinical outcome: 0–3 stars. Selected case-control studies that gained five or more stars were considered as of moderate to good quality [35].

Statistical analysis

In this study, the pooled ORs and their corresponding 95% CIs were used to evaluate the strength of the association between *IFN-* γ +874 A>T polymorphism and susceptibility to PTB. The heterogeneity assumption was tested by the χ^2 -based Q-test [36] and was considered statistically significant if the *p*-value was < 0.05 (means Q-test revealed a lack of heterogeneity among the selected studies). The data from single comparisons were pooled using a fixed effects model [37] when no heterogeneity was detected. Otherwise (in case of significant heterogeneity), the random-effects model [38] was applied for pooling of the data (ORs). In order to assess the ethnicity specific effect, sub-group analyses were performed by ethnic group. Furthermore, *I*² statistics was used to measure the inter-study variability ranging between 0 and 100%, wherein 0% indicates no observed heterogeneity and larger values 25%, 50%, and 75%, correspond to small, moderate, and high levels of heterogeneity, respectively [39]. The Hardy-Weinberg equilibrium (HWE) in the control group was calculated using the χ^2 test. Publication bias was evaluated using the funnel plot, wherein the standard error of log (OR) for each study was plotted against its log (OR) [40]. Furthermore, the Egger's linear regression test was used to measure the association between the mean effect estimate and its variance [41]. The significance of the intercept was measured by the *t*-test considering a *p*-value < 0.05 as a representation of statistically significant publication bias. Before the statistical analysis, a comparative appraisal of 'meta-analysis' software programs was performed by using the web-link: http://www. meta-analysis.com/pages/comparisons.html. The Comprehensive Meta-Analysis (CMA) Version 2 software program (Biostat, NJ, USA) was used to perform all the statistical analysis involved in this meta-analysis.

Results

Characteristics of the studies included in this meta-analysis

A systematic flow-diagram displaying the selection of published studies following the pre-set inclusion and exclusion criteria is shown in Figure 1. After many levels of screening (as per the pre-set




Figure 1. PRISMA Flow-diagram showing identification and selection of the studies for this metaanalysis

inclusion and exclusion criteria of study selection) a total of 21 case-control research publications were finally selected after a literature search of the PubMed (Medline), EMBASE, and Google Scholar web-databases [12-32]. Research publication either reporting IFN- γ +874 A>T polymorphism to predict survival in PTB patients or considering genetic variants as indicators for response to therapy were disqualified straightaway. Likewise, studies exploring the levels of IFN- γ mRNA or protein expression or pertinent review articles were also eliminated from this study. We incorporated only case-control or cohort design studies mentioning the frequency of all three genotypes. Moreover, the supporting references listed in the retrieved research publications were also scrutinised for other pertinent research publications. After cautious screening, the detailed characteristics of 23 studies from 21 eligible original published research articles included in this meta-analysis are provided in Table I. Distribution of genotypes, HWE *p*-values in the controls, and susceptibility towards PTB are shown in Table II. All the selected 21 studies were inspected for their quality following the Newcastle-Ottawa Scale (NOS) and most of the studies (80%) scored five stars or more, indicating moderate to good quality (Table III).

Table I. Main characteristics of all studies included in the meta-analysis

First author and year [Ref. No]	Country	Ethnicity	Control	Cases	Study	Association
Hu et al., 2015 [12]	China	Asian	480	120	PB	No risk
Mabunda <i>et al.</i> , 2015 [13]	Brazil	Mixed	456	102	HB	No risk
Shen <i>et al.</i> , 2013 [14]	China	Asian	164	69	PB	No risk
Selma <i>et al.</i> , 2011 [15]	Tunisia	African	150	168	HB	AA genotype risk
Hashemi <i>et al.</i> , 2011 [16]	Iran	Asian	166	142	HB	AA genotype risk
Ansari <i>et al.,</i> 2011 [17]	Pakistan	Asian	166	102	PB	No risk
Vallinoto <i>et al.,</i> 2010 [18]	Brazil	Mixed	156	129	НВ	No risk
Wang et al., 2010 [19]	China	Asian	527	522	PB	No risk
Anand <i>et al</i> ., 2010 [20]	India	Asian	66	62	HB	No risk
Ansari <i>et al.</i> , 2009 [21]	Pakistan	Asian	188	111	HB	TT genotype risk
Selvaraj <i>et al.</i> , 2008 [22]	India	Asian	178	160	HB	No risk
Ding et al., 2008 [23]	China	Asian	310	266	HB	AA genotype risk
Wu et al., 2008 [24]	China	Asian	111	183	HB	No risk
Hwang et al., 2007 [25]	Korea	Asian	80	80	HB	No risk
Moran <i>et al</i> ., 2007 [26]	USA	Caucasian	64	139	PB	No risk
Moran <i>et al</i> ., 2007a [26]	USA	African American	174	204	PB	No risk
Moran <i>et al.,</i> 2007b [26]	USA	Hispanics	98	270	PB	No risk
Sallakci <i>et al.</i> , 2007 [27]	Turkey	Caucasian	115	319	PB	TT genotype decreased risk
Cooke <i>et al.</i> , 2006 [28]	West African	African	594	667	PB	No risk
Vidyarani <i>et al.</i> , 2006 [29]	India	Asian	127	129	HB	No risk
Etokebe <i>et al.</i> , 2006 [30]	Croatia	Caucasian	519	179	HB	No risk
López-Maderuelo <i>et al.,</i> 2003 [31]	Spain	Caucasian	100	113	РВ	AA genotype risk
Lio et al., 2002 [32]	Italy	Caucasian	97	45	HB	TT genotype decreased risk

First author and year			Control	s			Cases		HWE	Power
	Genotype		Minor allele	G	enotyp	e	Minor allele			
	AA	AT	TT	MAF	AA	AT	TT	MAF	P-value	•
Hu et al., 2015	212	201	67	0.34	74	36	10	0.23	0.35	0.980
Mabunda <i>et al</i> ., 2014	203	136	21	0.24	66	32	3	0.18	0.08	0.971
Shen <i>et al.</i> , 2013	2	29	133	0.89	0	18	51	0.86	0.01	0.641
Selma <i>et al.</i> , 2011	42	86	22	0.43	77	64	27	0.35	0.26	0.796
Hashemi <i>et al.</i> , 2011	22	111	33	0.53	40	84	18	0.42	0.11	0.781
Ansari <i>et al</i> ., 2011	65	80	21	0.36	30	48	24	0.47	0.04	0.712
Vallinoto et al., 2010	46	86	24	0.42	73	46	10	0.25	0.01	0.741
Wang <i>et al.,</i> 2010	425	91	10	0.10	427	80	14	0.10	0.28	0.999
Anand <i>et al.</i> , 2010	33	25	8	0.31	28	27	7	0.33	0.13	0.371
Ansari <i>et al.</i> , 2009	76	87	25	0.36	37	47	27	0.45	0.27	0.766
Selvaraj <i>et al</i> ., 2008	79	76	23	0.34	68	72	20	0.35	0.03	0.823
Ding <i>et al.</i> , 2008	164	114	32	0.28	169	81	16	0.21	0.04	0.975
Wu et al., 2008	91	18	2	0.09	148	32	3	0.10	0.83	0.758
Hwang <i>et al.</i> , 2007	59	21	0	0.13	66	13	1	0.09	0.98	0.460
Moran <i>et al.</i> , 2007	17	31	16	0.49	36	80	23	0.45	0.01	0.571
Moran <i>et al.</i> , 2007a	98	65	11	0.25	120	76	8	0.22	0.95	0.869
Moran <i>et al</i> ., 2007b	62	26	10	0.23	170	82	18	0.21	0.04	0.859
Sallakci <i>et al.</i> , 2007	31	58	26	0.47	115	157	47	0.39	0.47	0.916
Cooke <i>et al.,</i> 2006	415	166	13	0.16	488	159	20	0.14	0.05	0.999
Vidyarani <i>et al</i> ., 2006	55	52	20	0.36	61	54	14	0.31	0.91	0.689
Etokebe <i>et al.</i> , 2006	134	282	103	0.47	50	92	37	0.46	0.06	0.992
López-Maderuelo et al., 2003	31	50	19	0.44	62	40	11	0.27	0.07	0.595
Lio et al., 2002	25	47	25	0.50	11	30	4	0.42	0.07	0.410

Table II. Genotypic distribution of IFN-7 +874 A>T (rs2430561) gene polymorphism included in the meta-analysis

MAF – minor allele frequency, HWE – Hardy-Weinberg equilibrium.

Publication bias

Begg's funnel plot and Egger's test were applied to appraise the publication bias of the included studies. The shape of the funnel plot was almost symmetric (Supplementary Figure S1). The Egger's test did not show any evidence of publication bias (Table IV).

Heterogeneity analysis

In order to check heterogeneity among the selected studies, Q-test and l^2 statistics were used. The analysis revealed the presence of significant heterogeneity in all the models. Thus, a random effects model was applied to synthesise the data (Table IV) (Supplementary Figure S1).

Sensitivity analysis

Sensitivity analysis was done to examine the effect of each individual study on the pooled OR by deleting a single study each time. The results

revealed that no individual study affected the pooled OR significantly, suggesting stability of this meta-analysis (Figures 2 A, B).

Quantitative synthesis

All the 21 studies (yielding 23 case-control study groups) had desired data, conclusively of 4281 confirmed PTB cases and 5186 healthy controls, to calculate the pooled ORs. The results of pooled study demonstrated that IFN- γ +874 A>T polymorphism is associated with reduced risk of PTB susceptibility (protective effect) in the general population under all the genetic models, i.e. allelic contrast (T vs. A: p = 0.001; OR = 0.818, 95% CI: 0.723-0.926), homozygous (TT vs. AA: p = 0.017; OR = 0.715, 95% CI: 0.543-0.941), heterozygous (AT vs. AA: p = 0.002; OR = 0.782, 95% CI: 0.667-0.917), dominant (TT+AT vs. AA: p = 0.002; OR = 0.768, 95% CI: 0.652-0.906), and recessive (TT vs. AA+AT: *p* = 0.042; OR = 0.802, 95% CI: 0.649–0.992) genetic models (Figures 3 A, B).

Table III. Quality assessment conducted accordingto the Newcastle-Ottawa Scale for all studies in-cluded in the meta-analysis

First author	Quality indicators								
and year	Selection	Comparability	Exposure						
Hu <i>et a</i> l., 2015	***	*	*						
Mabunda <i>et al.,</i> 2015	***	*	**						
Shen <i>et a</i> l. 2013	****	*	**						
Selma <i>et al.,</i> 2011	***	*	**						
Hashemi <i>et al.</i> , 2011	***	*	**						
Ansari <i>et al.,</i> 2011	***	*	**						
Vallinoto et al., 2010	****	**	**						
Wang <i>et al.,</i> 2010	****	*	**						
Anand <i>et al.,</i> 2010	***	*	**						
Ansari <i>et al.</i> , 2009	***	*	**						
Selvaraj et al., 2008	***	*	***						
Ding <i>et al.,</i> 2008	***	*	**						
Wu et al., 2008	****	**	***						
Hwang et al., 2007	***	*	***						
Moran <i>et al.</i> , 2007	***	*	***						
Sallakci <i>et al.,</i> 2007	****	**	**						
Cooke <i>et al.,</i> 2006	***	*	**						
Vidyarani et al., 2006	***	*	***						
Etokebe <i>et al.</i> , 2006	***	*	**						
López- Maderuelo <i>et al.</i> , 2003	****	*	**						
Lio <i>et al.,</i> 2002	***	*	**						

Subgroup analysis

A subgroup analysis based on ethnicity (casecontrol study population under consideration) was also performed to explore its effect (Asian and Caucasian) on the association between *IFN-* γ +874 A>T and PTB risk.

Subgroup analysis of the Asian population

Out of 21 studies included for overall metaanalysis, 12 studies were of Asian populations and were included in the subgroup analysis. Significant heterogeneity was found in all the genetic models (Table V) (Supplementary Figure S2). So, random effect models were applied for the analyses. Overall, no significant association of *IFN-* γ +874 A>T SNP and PTB susceptibility was found in all the genetic models, i.e. allele (T vs. A: p = 0.292; OR = 0.899, 95% CI: 0.738-1.096), homozygous (TT vs. AA: p = 0.325; OR = 0.885, 95% Cl: 0.693-1.129), heterozygous (AT vs. AA: p = 0.100; OR = 0.838, 95% CI: 0.679–1.034), dominant (TT+AT vs. AA: p = 0.199; OR = 0.854, 95% CI: 0.670-1.087), and recessive (TT vs. AA+AT: p = 0.679; OR = 0.932, 95% CI: 0.670-1.298) genetic models (Figure 4).

Subgroup analysis of the Caucasian population

In the Caucasian population five studies were included for subgroup analysis. No significant publication bias and heterogeneity was noticed (Supplementary Figure S3), and thus fixed effect models were applied for all the genetic models (Table VI). Interestingly, we found significantly decreased risk of PTB (in relation with *IFN-* γ +874 A>T SNP) in allele (T vs. A: *p* = 0.001; OR = 0.782, 95% CI: 0.672-0.909), homozygous (TT vs. AA: p = 0.003; OR = 0.615, 95% CI: 0.448-0.844), dominant (TT+AT vs. AA: p = 0.010; OR = 0.735, 95% CI: 0.582–0.929), and recessive (TT vs. AA+AT: p = 0.011; OR = 0.701, 95% CI: 0.533-0.921) genetic models (Figure 5). However, the heterozygous model (AT vs. AA: p = 0.070; OR = 0.796, 95% CI: 0.622-1.019) did not show any risk of PTB in relation to *IFN*- γ +874 A>T SNP (Figure 5).

Discussion

The cytokine network plays an important role in homeostasis of the immune response. Genetic variations in cytokine genes have been described earlier and demonstrated to influence gene transcription, leading to inter-individual variations in cytokines and may result in abnormal or aberrant immune response, as seen in *M. tuberculosis* infection [42]. Various mechanisms have been described for the development of a protective immunity that prevents the progression of the active disease [43]. The candidate gene approach and association studies have identified various host genetic factors that affect the susceptibility to TB [43].

An earlier report demonstrated that immunoregulatory genes are important in modulating the host susceptibility to PTB because the first line of defence against *M. tuberculosis* involves the iden-

Comparisons	Egg	er's regression anal	ysis	Het	erogeneity analysi	Model used	
	Intercept	95% Confidence interval	<i>P</i> -value	Q-value	Pheterogeneity	l² (%)	for the meta-analysis
T vs. A	-0.64	-3.45 to 2.16	0.63	60.91	0.001	63.88	Random
TT vs. AA	-0.22	-2.34 to 1.89	0.82	52.84	0.001	58.37	Random
AT vs. AA	0.41	-1.56 to 2.38	0.66	49.29	0.001	55.37	Random
TT+AT vs. AA	0.01	-2.16 to 2.18	0.99	59.02	0.001	62.72	Random
TT vs. AA+AT	-0.76	-2.68 to 1.15	0.41	40.44	0.010	45.60	Random

Table IV. Statistics to test publication bias and heterogeneity in the meta-analysis: overall population




Figure 2. A – Sensitivity analysis to evaluate the influence of each study on the pooled OR by deleting a single study each time for the overall analysis (allelic contract (T vs. A), homozygous (TT vs. AA) and heterozygous (AT vs. AA) genetic models). Black squares represent the value of OR, and the size of the square indicates the inverse proportion relative to its variance. The horizontal line is the 95% CI of OR. B – Sensitivity analysis to evaluate the influence of each study on the pooled OR by deleting a single study each time for the overall analysis (dominant (TT+AT vs. AT) and recessive (TT vs. AA+AT) genetic models). The black squares represent the value of OR, and the size of the square indicates the inverse proportion relative to its variance. The horizontal line is the 95% CI of OR.




Figure 3. A – Forest plot of OR with 95% CI of PTB risk associated with the IFN- γ +874 A>T gene polymorphism for overall population (allelic contract (T vs. A), homozygous (TT vs. AA), heterozygous (AT vs. AA) genetic models). The black square represents the value of OR, and the size of the square indicates the inverse proportion relative to its variance. The horizontal line is the 95% CI of OR. B – Forest plot of OR with 95% CI of PTB risk associated with the IFN- γ +874 A>T gene polymorphism for the overall population (dominant (TT+AT vs. AT), recessive (TT vs. AA+AT) genetic models). The black square represents the value of OR, and the size of the square indicates the inverse proportion relative to its variance. The horizontal line is the 95% CI of OR

tification and uptake of the bacterium by macrophages and dendritic cells [44]. IFN- γ is a potent activator of macrophages, and clinical and experimental evidence showed that IFN- γ plays a key role in antimicrobial activities that regulate mycobacterial infection. In recent years, *IFN*- γ +874 A>T gene polymorphism has been widely studied for potential association with increased/reduced/ no risk of PTB, but the findings were inconsistent, and still the precise association between the *IFN*- γ +874 A>T SNP and PTB risk is inconclusive. This inconclusive finding warranted further studies

with large sample sizes for accurate estimation of the association between the *IFN-* γ +874 A>T gene polymorphism and PTB disease. Hence, in order provide a precise conclusion against the above-mentioned controversial results, a metaanalysis is thought to be needed to achieve more reliable and accurate statistical evidence on the association between *IFN-* γ +874 A>T SNP and PTB susceptibility. The pooled ORs generated from a large sample size and sufficient statistical power from various studies have the power to reduce the random errors [45].

Comparisons	Egge	er's regression anal	ysis	He	Model used			
	Intercept	95% Confidence interval	<i>P</i> -value	Q-value	Pheterogeneity	I² (%)	for the meta-analysis	
T vs. A	0.57	-3.97 to 5.12	0.78	36.02	0.001	69.46	Random	
TT vs. AA	0.58	-2.50 to 3.68	0.68	35.57	0.001	66.23	Random	
AT vs. AA	0.81	-1.76 to 3.35	0.49	19.92	0.046	44.77	Random	
TT+AT vs. AA	0.73	-2.32 to 3.79	0.60	29.05	0.002	62.14	Random	
TT vs. AA+AT	0.376	-2.72 to 3.47	0.79	23.46	0.015	53.11	Random	

Table V. Statistics to test publication bias and heterogeneity in the meta-analysis: Asian population

We included 23 case-control group studies from 21 published articles complying with all the eligible criteria. All the included studies scored five or more stars in NOS quality assessment and indicated good to moderate quality by clearly stating the sample size, genotype, and inclusion criteria of PTB patients and healthy controls. We found that pooled results of IFN- γ +874 A>T gene polymorphism for each genetic model as well as the allele contrast was significantly associated with decreased risk of PTB. These observations lead to the conclusion that that IFN- γ +874 A>T polymorphism leads to a protective role in PTB infection. This finding highlights that IFN- γ +874 A>T polymorphism may be an important marker with possible relevant application when dealing with the prognosis of PTB. An earlier meta-analysis also indicated a protective role of IFN- γ +874 A>T gene polymorphism in TB disease, based on only 11 studies [11] (case-control series) due to the limited availability of the data at that time, with no clear-cut differentiation of overall TB into PTB and extra-pulmonary TB, and lack of subgroup analysis.

The importance of IFN- γ in TB has been difficult to establish. IFN- γ is critical to activation of macrophages during mycobacterial infection. Certainly, many studies have shown that the levels of IFN- γ are lower in subjects with active TB than in controls, suggesting a protective role of this cytokine [8].

The genotype frequency of *IFN-* γ +874 A>T vary greatly in different ethnicities. Previous studies have shown that there is a discrepancy in TB susceptibility among different ethnicities [46]. Hence, we conducted subgroup analysis by ethnicity, and our results showed that the *IFN-* γ +874 A>T genotype is significantly associated with decreased PTB risk in the Caucasian population and provides a protective effect. Whereas, no significant association between *IFN-* γ +874 A>T and PTB susceptibility was found in the Asian ethnic population. In this manner, our subgroup analysis at least presents evidence for the racial differences of *IFN-* γ +874 A>T polymorphism and its effects. However,

TB susceptibility genes in genome-wide screens endorsed the possibility of multigenic predisposition of TB [47, 48]. However, due to the multifactorial nature of TB infection and complex nature of the immune system, *IFN*- γ +874 A>T gene polymorphism cannot be solely accountable for the predisposition of PTB.

In this study, significant heterogeneity was found between the selected studies during the heterogeneity evaluation. This limitation was in line with a previously published meta-analysis, which reported significant heterogeneity across the studies under consideration [11]. This may be due to some factors, e.g. the ethnicity, selection of method, the definition of cases, and the sample size. However, our study has some limitations, hence it is worth mentioning for their redressal in future studies. First, we only selected studies published in the English language, abstracted and indexed by the specific web-databases for data analysis; it is possible that some relevant studies published in other languages and abstracted and indexed in other databases may have been missed. Second, the extrapolated data were not stratified by other factors, e.g. HIV infection status or severity of the PTB infection, and these results are based on the above-mentioned unadjusted parameters. Infection is the 'combine effect' of the interaction between the host, the parasite, and the environment, and is superimposed on the continual evolution and adaptation of the microbial and human genomes to each other [49]. Third, we failed to test gene-gene and gene-environment interactions, due to lack of adequate data available in the published reports; the interaction of different susceptibility genes and environmental factors can lead to the disease.

Notwithstanding the above limitations, there are some advantages associated with our study. First, this meta-analysis included a greater number of studies (which were not incorporated earlier) to increase the statistical power and attain robust conclusions. Second, publication bias did not exist, and sensitivity analysis also aided the Odds ratio and 95% CI

	1000	mm	mm	2-value	p-value				
Hu et al. 2015	0.568	0.409	0.788	-3.390	0.001		+₽		
Shen et al. 2013	0.746	0.404	1.376		0.348		_ +=	+	
Hashemi et al. 2011	0.641	0.466	0.882		0.006		†■-		
Ansari et al. 2011	1.530	1.074	2.180		0.019		.	1	
Wang et al. 2010	0.980	0.741	1.297		0.889		1		
Anand et al. 2010	1.096	0.648	1.854		0.731		-		
Ansari et al. 2009	1.456	1.039	2.041		0.029				
Selvaraj et al. 2008	0.670	0.752	1.418		0.842			-	
Ding et al. 2008	1.053	0.511	1.832		0.004				
Wu et al. 2008	0.685	0.805	1.882		0.854				
Hwang et al. 2007 Vidyarani et al. 2006	0.820	0.569	1.183	-1.057	0.290				
vioyarani et al. 2000	0.820	0.738	1.096		0.299			τ	
	0.000	0.750	1.000	-1.004	0.696			1 2	I I 5 10
						0.1	0.2 0.5	1 2 1	5 10
Study name		Statisti	cs for e	ach study			Odds ratio	and 95% CI	
				acti atady			00001000		
TT vs. AA	Odds ratio	Lower	Upper limit	Z-Value	n-Value				
Hu et al. 2015	0.428	0.209	0.874	-2.328	0.020				
Shen et al. 2013	1.929	0.091	40.864	0.422	0.673		-		-
Hashemi et al. 2011 Ansari et al. 2011	2.476	1.196	5,129	-3.045	0.002				
	1.393	0.612	3.172	0.791	0.015				
Wang et al. 2010 Anand et al. 2010	1.031	0.332	3.200	0.053	0.958				
Ansari et al. 2009	2.218	1.134	4.340	2.327	0.020				
Selvaraj et al. 2008	1.010	0.511	1.997	0.029	0.977		-		
Ding et al. 2008	0.485	0.257	0.918	-2.224	0.026			F	
Wu et al. 2008	0.922	0.151	5.625	0.088	0.930				
Hwang et al. 2007	2.684	0.107	67.156	0.601	0.548			┝╼┼┝	-1
Vidyarani et al. 2006	0.631	0.291	1.369	-1.165	0.244		_ − ∎	F 1	
	0.885	0.693	1.129	-0.984	0.325			k	
						0.01	0.1	1 10	100
Study name		Ctatisti		h study			Odda ratio	and 95% CI	
				ich study			Ouus ratio	and 86% CI	
AT vs. AA		Lower	Upper						
	ratio	limit	limit	Z-Value	p-Value				
Hu et al. 2015	0.513	0.330	0.799	-2.955	0.003		₩		
Shen et al. 2013	3.136		69.015	0.725	0.469			┝╺┼╴	-1
Hashemi et al. 2011	0.416	0.230	0.753	-2.900	0.004		-∎-		
Ansari et al. 2011	1.300	0.742	2.279	0.916	0.360			-	
Wang et al. 2010	0.875	0.630	1.216	-0.795	0.426				
Anand et al. 2010	1.273	0.607	2.671	0.638	0.524				
Ansari et al. 2009	1.110	0.654	1.884	0.385	0.700				
Selvaraj et al. 2008	1.101	0.697	1.739	0.411	0.680		1 1		
Ding et al. 2008	0.690	0.483	0.985	-2.042					
Ding of all 2000					0.041			L I	
Wu et al. 2008	1.093	0.580	2.060	0.275	0.783		- I - E	▶	
Wu et al. 2008 Hwang et al. 2007	1.093 0.553	0.580	2.060	0.275	0.783 0.135				
Wu et al. 2008	1.093 0.553 0.936	0.580 0.255 0.553	2.060 1.202 1.586	0.275 -1.495 -0.245	0.783 0.135 0.807				
Wu et al. 2008 Hwang et al. 2007	1.093 0.553	0.580	2.060	0.275	0.783 0.135				
Wu et al. 2008 Hwang et al. 2007	1.093 0.553 0.936	0.580 0.255 0.553	2.060 1.202 1.586	0.275 -1.495 -0.245	0.783 0.135 0.807	0.01	0.1	- - 1 10	100
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2005	1.093 0.553 0.936	0.580 0.255 0.553 0.679	2.060 1.202 1.586 1.034	0.275 -1.495 -0.245 -1.644	0.783 0.135 0.807	0.01			100
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2006 Study name	1.093 0.553 0.936 0.838	0.580 0.255 0.553 0.679 Statisti	2.060 1.202 1.586 1.034	0.275 -1.495 -0.245	0.783 0.135 0.807	0.01	0.1		100
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2005	1.093 0.553 0.936 0.838 Odds	0.580 0.255 0.553 0.679 Statisti	2.060 1.202 1.586 1.034	0.275 -1.495 -0.245 -1.644 ach study	0.783 0.135 0.807 0.100	0.01			100
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2006 Study name TT + AT vs. AA	1.093 0.553 0.936 0.838 Odds ratio	0.580 0.255 0.553 0.679 Statisti Lower limit	2.060 1.202 1.586 1.034 cs for ei Upper limit	0.275 -1.495 -0.245 -1.644 ach study Z-Value	0.783 0.135 0.807 0.100 p-Value	0.01			100
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2006 Study name TT + AT vs. AA Hu et al. 2015	1.093 0.553 0.936 0.838 Odds ratio 0.492	0.580 0.255 0.553 0.679 Statisti Lower limit 0.326	2.060 1.202 1.586 1.034 cs for ea Upper limit 0.741	0.275 -1.495 -0.245 -1.644 ach study Z-Value -3.396	0.783 0.135 0.807 0.100 p-Value 0.001	0.01			100
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2006 Study name TT + AT vs. AA Hu et al. 2015 Shen et al. 2013	1.093 0.553 0.936 0.838 Odds ratio 0.492 2.138	0.580 0.255 0.553 0.679 Statisti Lower limit 0.326 0.101	2.060 1.202 1.586 1.034 Cs for ei Upper limit 0.741 45.124	0.275 -1.495 -0.245 -1.644 ach study Z-Value -3.396 0.489	0.783 0.135 0.807 0.100 p-Value 0.001 0.625	0.01			100
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2006 Study name TT + AT vs. AA Hu et al. 2015 Shen et al. 2013 Hashemi et al. 2013	1.093 0.553 0.936 0.838 Odds ratio 0.492 2.138 0.390	0.580 0.255 0.553 0.679 Statisti Lower limit 0.326 0.101 0.218	2.060 1.202 1.586 1.034 Cs for ei Upper limit 0.741 45.124 0.695	0.275 -1.495 -0.245 -1.644 ach study Z-Value -3.396 0.489 -3.192	0.783 0.135 0.807 0.100 p-Value 0.001 0.625 0.001	0.01			100
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2006 Study name TT + AT vs. AA Hu et al. 2015 Shen et al. 2013 Hashemi et al. 2011	1.093 0.553 0.936 0.838 Odds ratio 0.492 2.138 0.390 1.545	0.580 0.255 0.553 0.679 Statisti Lower limit 0.326 0.101 0.218 0.911	2.060 1.202 1.586 1.034 Upper Ilmit 0.741 45.124 0.695 2.618	0.275 -1.495 -0.245 -1.644 ach study Z-Value -3.396 0.489 -3.192 1.614	0.783 0.135 0.807 0.100 p-Value 0.001 0.625 0.001 0.106	0.01			100
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2006 TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Hashemi et al. 2011 Ansari et al. 2011	1.093 0.553 0.936 0.838 Odds ratio 0.492 2.138 0.390 1.545 0.926	0.580 0.255 0.553 0.679 Statisti Lower limit 0.326 0.101 0.218 0.911 0.679	2.060 1.202 1.586 1.034 Cs for ex Upper limit 0.741 45.124 0.695 2.618 1.265	0.275 -1.495 -0.245 -1.644 ach study Z-Value -3.396 0.489 -3.192 1.614 -0.482	0.783 0.135 0.807 0.100 p-Value 0.001 0.625 0.001 0.106 0.630	0.01			100
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2007 TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Hashemi et al. 2011 Wang et al. 2011 Wang et al. 2010	1.093 0.553 0.936 0.838 Odds ratio 0.492 2.138 0.390 1.545	0.580 0.255 0.553 0.679 Statisti Lower limit 0.326 0.101 0.218 0.911 0.679 0.606	2.060 1.202 1.586 1.034 Upper limit 0.741 45.124 0.695 2.618 1.265 2.433	0.275 -1.495 -0.245 -1.644 ach study Z-Value -3.396 0.489 -3.192 1.614 -0.482 0.548	0.783 0.135 0.807 0.100 p-Value 0.001 0.625 0.001 0.106	0.01			100
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2007 TT + AT vs. AA Hu et al. 2015 Shen et al. 2013 Hashemi et al. 2011 Ansari et al. 2010 Anand et al. 2010 Ansari et al. 2009	1.093 0.553 0.936 0.838 Odds ratio 0.492 2.138 0.390 1.545 0.926 1.214	0.580 0.255 0.553 0.679 Statisti Lower limit 0.326 0.101 0.218 0.911 0.679	2.060 1.202 1.586 1.034 Cs for ex Upper limit 0.741 45.124 0.695 2.618 1.265	0.275 -1.495 -0.245 -1.644 ach study Z-Value -3.396 0.489 -3.192 1.614 -0.482	0.783 0.135 0.807 0.100 p-Value 0.001 0.625 0.001 0.106 0.630 0.584	0.01			100
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2007 Vidyarani et al. 2006 TT + AT vs. AA Hu et al. 2015 Shon et al. 2011 Mansari et al. 2011 Mansari et al. 2011 Ansari et al. 2011 Ansari et al. 2010 Ansari et al. 2010	1.093 0.553 0.936 0.838 0.838 0.492 2.138 0.492 2.138 0.390 1.545 0.926 1.214 1.357	0.580 0.255 0.553 0.679 Statisti Lower limit 0.326 0.101 0.218 0.911 0.606 0.831	2.060 1.202 1.586 1.034 Cs for ex Upper limit 0.741 45.124 0.695 2.618 1.265 2.433 2.216 1.661	0.275 -1.495 -0.245 -1.644 z-Value -3.396 0.489 -3.192 1.614 -0.482 0.548 1.220 0.348	0.783 0.135 0.807 0.100 p-Value 0.001 0.625 0.001 0.106 0.630 0.584 0.222	0.01			100
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2007 TT + AT vs. AA Hu et al. 2015 Shen et al. 2013 Hashemi et al. 2011 Ansari et al. 2010 Anand et al. 2010 Ansari et al. 2009	1.093 0.553 0.936 0.838 0.838 0.492 2.138 0.390 1.545 0.926 1.214 1.357 1.080	0.580 0.255 0.553 0.679 Statisti Lower limit 0.326 0.101 0.218 0.911 0.679 0.6679 0.831 0.702	2.060 1.202 1.586 1.034 cs for ex Upper limit 0.741 45.124 0.695 2.618 1.265 2.433 2.216	0.275 -1.495 -0.245 -1.644 z-Value -3.396 0.489 -3.192 1.614 -0.482 0.548 1.220 0.548 1.220 0.348 -2.570 0.236	0.783 0.135 0.807 0.100 p-Value 0.001 0.625 0.001 0.106 0.630 0.530 0.222 0.727	0.01			100
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2007 TT + AT vs. AA Hu et al. 2015 Shen et al. 2013 Hasherni et al. 2011 Ansari et al. 2010 Anand et al. 2010 Anand et al. 2010 Ding et al. 2008 Wu et al. 2008	1.093 0.553 0.936 0.838 0.838 0.492 2.138 0.492 2.138 0.390 1.545 0.926 1.214 1.357 1.080 0.645 1.065 6.596	0.580 0.255 0.553 0.679 Statisti Lower limit 0.326 0.101 0.218 0.911 0.679 0.606 0.831 0.702 0.461 0.583	2.060 1.202 1.586 1.034 Upper limit 0.741 45.124 0.695 2.618 1.265 2.433 2.216 1.661 0.901 1.977 1.277	0.275 -1.495 -0.245 -1.644 ach study Z-Value -3.396 0.489 -3.192 1.614 -0.482 0.548 1.220 0.348 1.220 0.348 -2.576 -1.331	0.783 0.135 0.807 0.100 p-Value 0.001 0.625 0.001 0.106 0.630 0.530 0.222 0.727 0.010 0.813 0.183	0.01			100
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2007 Study name TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Hashemi et al. 2011 Wang et al. 2010 Ansari et al. 2019 Ansari et al. 2019 Ding et al. 2010 Wu et al. 2008	1.093 0.553 0.936 0.838 0.838 0.838 0.926 1.214 1.357 1.080 0.645 1.076 0.596 0.852	0.580 0.255 0.553 0.679 Statisti Lower Ilmit 0.326 0.911 0.218 0.911 0.679 0.606 0.831 0.702 0.461 0.586 0.278 0.528	2.060 1.202 1.586 1.034 Upper limit 0.741 45.124 0.695 2.618 1.265 2.433 2.216 1.661 0.901 1.977 1.277 1.394	0.275 -1.495 -0.245 -1.644 z-Value -3.396 0.489 -3.192 1.614 -0.482 0.548 1.220 0.348 -2.570 0.348 -1.331 -0.639	0.783 0.135 0.807 0.100 p-Value 0.001 0.625 0.001 0.625 0.001 0.630 0.630 0.584 0.222 0.727 0.010 0.813 0.183 0.523	0.01			100
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2007 TT + AT vs. AA Hu et al. 2015 Shen et al. 2013 Hasherni et al. 2011 Ansari et al. 2010 Anand et al. 2010 Anand et al. 2010 Ding et al. 2008 Wu et al. 2008	1.093 0.553 0.936 0.838 0.838 0.492 2.138 0.492 2.138 0.390 1.545 0.926 1.214 1.357 1.080 0.645 1.065 6.596	0.580 0.255 0.553 0.679 Statisti Lower limit 0.326 0.101 0.218 0.911 0.679 0.606 0.831 0.702 0.461 0.583	2.060 1.202 1.586 1.034 Upper limit 0.741 45.124 0.695 2.618 1.265 2.433 2.216 1.661 0.901 1.977 1.277	0.275 -1.495 -0.245 -1.644 z-Value -3.396 0.489 -3.192 1.614 -0.482 0.548 1.220 0.348 -2.570 0.236 -1.331	0.783 0.135 0.807 0.100 p-Value 0.001 0.625 0.001 0.106 0.630 0.530 0.222 0.727 0.010 0.813 0.183	0.01			100
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2007 TT + AT vs. AA Hu et al. 2015 Shen et al. 2013 Hasherni et al. 2011 Ansari et al. 2010 Anand et al. 2010 Anand et al. 2010 Ding et al. 2008 Wu et al. 2008	1.093 0.553 0.936 0.838 0.838 0.838 0.926 1.214 1.357 1.080 0.645 1.076 0.596 0.852	0.580 0.255 0.553 0.679 Statisti Lower Ilmit 0.326 0.911 0.218 0.911 0.679 0.606 0.831 0.702 0.461 0.586 0.278 0.528	2.060 1.202 1.586 1.034 Upper limit 0.741 45.124 0.695 2.618 1.265 2.433 2.216 1.661 0.901 1.977 1.277 1.394	0.275 -1.495 -0.245 -1.644 z-Value -3.396 0.489 -3.192 1.614 -0.482 0.548 1.220 0.348 -2.570 0.348 -1.331 -0.639	0.783 0.135 0.807 0.100 p-Value 0.001 0.625 0.001 0.625 0.001 0.630 0.630 0.584 0.222 0.727 0.010 0.813 0.183 0.523				100
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2007 TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Hashemi et al. 2011 Ansari et al. 2011 Ansari et al. 2010 Selvaraj et al. 2008 Wu et al. 2008 Wu et al. 2006 Wu et al. 2006	1.093 0.553 0.936 0.838 0.838 0.838 0.926 1.214 1.357 1.080 0.645 1.076 0.596 0.852	0.580 0.255 0.553 0.679 Statisti limit 0.326 0.101 0.218 0.911 0.679 0.606 0.831 0.702 0.461 0.586 0.278 0.520 0.670	2.060 1.202 1.586 1.034 Upper <i>limit</i> 0.741 45.124 0.695 2.618 1.265 2.433 2.216 1.661 0.901 1.977 1.394 1.087	0.275 -1.495 -0.245 -1.644 ach study Z-Value -3.396 0.489 -3.192 1.614 -0.482 0.548 1.220 0.548 1.220 0.348 -2.570 0.236 -1.331 -0.639 -1.284	0.783 0.135 0.807 0.100 0.100 0.625 0.001 0.106 0.634 0.222 0.727 0.610 0.813 0.199		Odds ratio a	2 5	*
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2007 TT + AT vs. AA Hu et al. 2015 Shen et al. 2013 Hasherni et al. 2011 Mang et al. 2010 Ansari et al. 2019 Ansari et al. 2019 Ansari et al. 2019 Mu et al. 2008 Hwang et al. 2006 Hwang et al. 2006 Hwang et al. 2006 Hwang et al. 2006	1.093 0.553 0.936 0.838 0.838 0.390 0.492 2.138 0.390 1.545 0.926 1.214 1.357 1.080 0.845 1.076 0.552 0.854	0.580 0.255 0.553 0.679 Statisti Lower limit 0.326 0.101 0.218 0.911 0.679 0.606 0.831 0.702 0.666 0.831 0.526 0.461 0.586 0.278 0.520 0.670	2.060 1.202 1.586 1.034 Upper limit 0.741 45.124 0.695 2.433 2.216 1.661 0.901 1.977 1.277 1.394 1.087	0.275 -1.495 -0.245 -1.644 z-Value -3.396 0.489 -3.192 1.614 -0.482 0.548 1.220 0.348 -2.570 0.348 -1.331 -0.639	0.783 0.135 0.807 0.100 0.100 0.625 0.001 0.106 0.634 0.222 0.727 0.610 0.813 0.199		Odds ratio a	and 95% Cl	*
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2007 TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Hashemi et al. 2011 Ansari et al. 2011 Ansari et al. 2010 Selvaraj et al. 2008 Wu et al. 2008 Wu et al. 2006 Wu et al. 2006	1.093 0.553 0.936 0.838 0.838 0.492 2.138 0.920 1.545 0.926 0.390 1.545 0.926 0.390 1.214 1.357 1.080 0.645 0.852 0.854 0.854	0.580 0.255 0.553 0.679 Statisti Lower limit 0.326 0.101 0.218 0.218 0.218 0.218 0.218 0.218 0.218 0.218 0.421 0.670 0.680 0.451 0.659 0.451 0.520 0.670 Statisti Lower	2.060 1.202 1.586 1.034 Upper Iimit 0.741 45.124 0.995 2.618 1.265 2.433 2.216 1.661 0.901 1.977 1.277 1.394 1.087 Cs for e: Upper	0.275 -1.495 -0.245 -1.644 z-Value -3.396 0.489 -3.192 1.614 -0.482 0.548 1.220 0.348 -2.570 0.348 -2.570 0.348 -2.284 ach study	0.783 0.135 0.807 0.100 p-Value 0.001 0.625 0.001 0.106 0.630 0.584 0.222 0.727 0.010 0.813 0.1813 0.523 0.199		Odds ratio a	2 5	*
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2007 Vidyarani et al. 2006 TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Hashemi et al. 2011 Wang et al. 2010 Ansari et al. 2019 Ansari et al. 2019 Ansari et al. 2008 Hwang et al. 2008	1.093 0.553 0.936 0.838 0.838 0.492 2.138 0.926 1.214 1.357 1.060 0.645 1.274 0.596 0.352 0.854 0.854 0.854	0.580 0.255 0.553 0.679 Statisti 0.326 0.679 0.301 0.218 0.301 0.679 0.606 0.331 0.679 0.606 0.331 0.679 0.666 0.331 0.520 0.670 Statisti	2.060 1.202 1.586 1.034 Upper Iimit 0.741 45.124 0.995 2.618 1.265 2.433 1.265 2.433 1.265 2.431 1.087 1.977 1.394 1.087 Upper Upper I mit	0.275 -1.495 -0.245 -1.644 z-Value -3.396 0.489 -3.192 1.614 -0.482 0.548 1.220 0.548 1.220 0.548 1.220 0.548 1.220 0.548 1.220 0.236 -1.339 -1.284 z-Value z-Value	0.783 0.135 0.807 0.100 p-Value 0.001 0.625 0.001 0.625 0.001 0.630 0.630 0.584 0.222 0.727 0.727 0.813 0.183 0.523 0.199 p-Value		Odds ratio a	2 5	*
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2007 Vidyarani et al. 2006 TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Hasherni et al. 2011 Mang et al. 2010 Ansari et al. 2019 Ansari et al. 2008 Hwang et al. 2006 Hwang et al	1.093 0.553 0.838 0.838 0.838 0.838 0.390 1.545 1.214 1.357 1.080 0.926 1.214 1.357 0.926 1.214 1.080 0.926 0.926 0.926 0.926 0.926 0.926 0.936 0.9566 0.956 0.956 0.956 0.95666 0.9566 0.9566 0.9566 0.9566 0.95666 0.9566 0.9566 0.9566 0.9	0.580 0.255 0.679 Statisti Lower limit 0.326 0.101 0.79 0.679 0.631 0.791 0.679 0.631 0.792 0.641 0.780 0.670 0.670 0.586 0.2780 0.679	2.060 1.202 1.586 1.034 Upper limit 0.741 1.855 2.433 2.216 1.661 1.977 1.277 1.277 1.294 1.087 1.394 1.087	0.275 -1.495 -0.245 -1.644 ach study Z-Value -3.396 0.489 -3.192 1.614 -0.482 0.548 1.220 0.348 1.220 0.348 -2.570 0.236 -1.331 -0.639 -1.284 Z-Value Z-Value -3.395 Z-Value -1.644 Z-Value -3.395 Z-Value -1.644 Z-Value -3.452 Z-Value -1.284 Z-Value -1.284 Z-Value -1.284 Z-Value -1.284 Z-Value -1.284 Z-Value -1.284 Z-Value -1.284 Z-Value -1.284 Z-Value -1.284 Z-Value Z-Value Z-Value Z-Value -1.284 Z-Value -1.284 Z-Value Z-Value Z-Value -1.284 Z-Value Z-Value -1.284 Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value Z-Value 	0.783 0.807 0.807 0.100 p-Value 0.001 0.625 0.001 0.625 0.001 0.625 0.625 0.630 0.584 0.222 0.727 0.010 0.813 0.183 0.183 0.199 2.523 0.199		Odds ratio a	2 5	*
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2007 Vidyarani et al. 2006 TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Hashemi et al. 2011 Ansari et al. 2011 Ansari et al. 2010 Anand et al. 2010 Ding et al. 2008 Wu et al. 2007 Vidyarani et al. 2006 Wu ag et al. 2006 Wu ag et al. 2006 TT vs. AA + AT Hu et al. 2015 Shon et al. 2013	1.093 0.553 0.838 0.838 0.838 0.838 0.838 0.838 1.242 1.244 1.357 1.080 0.645 1.274 0.586 0.852 0.854	0.580 0.255 0.553 0.679 Statisti Lower limit 0.326 0.326 0.326 0.326 0.326 0.326 0.326 0.321 0.702 0.461 0.590 0.451 0.520 0.670 Statisti Lower Iimit 0.278 0.553 0.326 0.326 0.321 0.553 0.326 0.321 0.553 0.326 0.321 0.321 0.553 0.326 0.321 0.321 0.553 0.321 0.321 0.321 0.321 0.553 0.321 0.322 0.321 0.321 0.322 0.321 0.321 0.322 0.321 0.321 0.322 0.321 0.321 0.322 0.321 0.322 0.321 0.321 0.321 0.550 0.550 0.321 0.320 0.550 0.321 0.320 0.321 0.320 0.321 0.320 0.321 0.320 0.321 0.320 0.321 0.320 0.321 0.320 0.321 0.320 0.321 0.3200 0.3200 0.3200 0.3200 0.3200 0.3200 0.3200 0.3200 0.32000 0.32000 0.320000000000	2.060 1.202 1.586 1.034 Upper Ilmit 0.741 45.124 0.895 2.618 1.265 2.433 2.216 1.661 1.977 1.277 1.277 1.394 1.087 Upper Ilmit 1.394 1.087	0.275 -1.495 -0.245 -1.644 z.Value z.Value -3.396 0.489 -3.192 1.614 -0.482 -3.192 1.614 -0.482 -0.482 -0.482 -0.548 1.220 0.236 -1.284 x.Value -1.629 -1.224	0.783 0.135 0.807 0.100 0.100 0.100 0.625 0.001 0.106 0.630 0.524 0.727 0.727 0.010 0.813 0.199 0.523 0.199		Odds ratio a	2 5	*
Wu et al. 2008 Study name TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Mashemi et al. 2013 Hashemi et al. 2014 Manard et al. 2013 Ansari et al. 2019 Ansari et al. 2019 Migurani et al. 2010 Wu et al. 2006 Hwang et al. 2007 Vidyarani et al. 2009 Study name TT vs. AA + AT Hu et al. 2015 Shen et al. 2015 Shen et al. 2015	1.093 0.553 0.936 0.838 0.492 0.492 0.492 1.345 0.926 1.214 1.345 0.926 1.214 1.080 0.845 1.076 0.852 0.854 Odds ratio 0.452 0.854	0.580 0.255 0.653 0.659 Statisti Lower Ilimit 0.326 0.321 0.461 0.579 0.461 0.579 0.461 0.579 0.461 0.579 0.461 0.579 0.461 0.579 0.461 0.579 0.461 0.579 0.461 0.579	2.060 1.202 1.586 1.034 0.095 2.618 2.433 2.216 0.901 1.265 2.433 2.216 0.901 1.977 1.394 1.087 0.901 1.977 1.394 1.087	0.275 -1.495 -0.245 -1.644 ach study Z-Value -3.396 -0.482 -3.192 1.614 -0.482 -0.482 0.489 -3.192 1.614 -0.482 0.348 -1.200 -0.236 -1.224 ach study Z-Value -1.284 Z-Value -1.284 Z-Value -1.284	0.783 0.135 0.807 0.100 p-Value 0.001 0.482 0.4825 0.4825 0.4825 0.4825 0.4825 0.4825 0.4825 0.483 0.483 0.483 0.483 0.483 0.483 0.483 0.483 0.484 0.484 0.484 0.484 0.484 0.484 0.485 0.499 0.499 0.490 0		Odds ratio a	2 5	*
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2007 Vidyarani et al. 2006 TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Hashemi et al. 2011 Wang et al. 2010 Anand et al. 2010 Anand et al. 2010 Anand et al. 2008 Wu et al. 2008 Wu et al. 2008 Wu et al. 2008 Wu et al. 2008 Study name TT vs. AA + AT Hu et al. 2013 Hashemi et al. 2011 Masari et al. 2013	1.093 0.553 0.936 0.838 0.838 0.390 0.492 2.138 0.390 1.545 0.926 1.214 1.357 1.080 0.645 0.854 0.854 0.854 0.855 0.856	0.580 0.255 0.653 0.653 0.679 Statiati 0.326 0.011 0.326 0.321 0.218 0.321 0.421 0.421 0.520 0.670 Statiati Lower Ilimit Lower 0.679 0.461 0.533 0.679	2.060 1.202 1.586 1.686 1.686 1.686 1.686 1.686 1.686 1.686 1.686 1.686 1.686 1.687 1.977 1.377 1.377 1.1087 1.1087 1.1285 1.283 1.082 1.283 1.285 1.283 1.283 1.285 1.283 1.285	0.275 -1.485 -0.245 -1.644 ach study Z Value -3.396 -0.489 -3.192 -3.192 -3.192 -3.192 -3.192 -3.192 -3.192 -3.192 -3.192 -3.192 -3.192 -3.282 -1.284 ach study Z Value Z Value Z Value -1.629 -1.629 -1.624 -1	0.783 0.135 0.807 0.100 0.625 0.001 0.625 0.016 0.625 0.016 0.625 0.016 0.524 0.727 0.584 0.584 0.523 0.199 P-Value 0.625 0.523 0.199		Odds ratio a	2 5	*
Wu et al. 2008 Study name TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Hasherni et al. 2014 Manari et al. 2015 Shon et al. 2013 Hasherini et al. 2011 Wang et al. 2010 Migurani et al. 2009 Wu et al. 2006 Hwang et al. 2007 Vidyarani et al. 2006 Study name TT vs. AA + AT Hu et al. 2015 Shen et al. 2015	1.093 0.553 0.936 0.838 0.838 0.492 2.138 0.492 2.138 1.214 1.214 1.214 1.257 1.090 0.845 0.856 0.856 0.852 0.854 Odds ratio 0.596 0.855 0.855 0.855 0.855 0.855	0.580 0.255 0.653 0.653 0.659 Statisti Uover 1limit 0.326 0.481 0.421 0.650 0.431 0.650 0.481 0.520 0.470 Statisti Uover Ilimit 0.278 0.530 0.451 0.532 0.451 0.532 0.531 0.532 0.531 0.532 0.531 0.532 0.531 0.533 0.533 0.556 0.553 0.557 0.557 0.557 0.557 0.557 0.557 0.576 0.576 0.576 0.570 0.57	2.060 1.202 1.586 1.303 Upper limit 0.741 45.124 0.995 2.618 1.661 0.901 1.397 1.394 1.087 Upper limit 1.125 1.087 Upper limit 1.222 4.058 3.237	0.275 -1.495 -0.245 -1.644 ach study Z.Value -3.396 -0.489 -3.192 -1.644 -0.482 0.482 -0.482 0.482 -0.549 -0.482 0.348 ach study Z.Value -1.284 ach study Z.Value -1.284 ach study -1.284 ach study -1.284 ach study -1.284 ach study -1.284 ach study -1.284 -1.683 2.282 0.846 -1.224 -1.683 2.822 -1.244 -1.683 2.822 -1.244 -1.683 2.822 -1.244 -1.683 2.822 -1.244 -1.683 2.822 -1.244 -1.244 -1.244 -1.245 -1.2444 -1.2444 -1.244 -1.244 -1.244 -1.2	0.783 0.35 0.807 0.100 p-Value 0.001 0.620 0.001 0.630 0.001 0.630 0.584 0.222 0.108 0.584 0.582 0.199 p-Value 0.013 0.582 0.199		Odds ratio a	2 5	*
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2007 Vidyarani et al. 2006 TT + AT vs. AA Hu et al. 2015 Shon et al. 2015 Mashen et al. 2011 Wang et al. 2010 Ansari et al. 2010 Ansari et al. 2000 Vidyarani et al. 2000 Vidyarani et al. 2000 Vidyarani et al. 2007 Vidyarani et al. 2007 Study name TT vs. AA + AT Hu et al. 2015 Shon et al. 2013 Masheni et al. 2011 Wang et al. 2011 Wang et al. 2011	1.093 0.553 0.936 0.838 0.838 0.398 0.492 2.138 0.390 0.492 2.138 0.390 0.492 2.138 0.390 0.492 1.214 1.357 1.080 0.645 0.585 0.854 0.685 0.685 0.685 0.685 2.125 1.425 0.685	0.580 0.255 0.679 Statisti Lower limit 0.326 0.101 0.218 0.101 0.218 0.911 0.218 0.911 0.218 0.911 0.218 0.911 0.586 0.702 0.461 0.530 0.702 0.460 0.533 0.779 0.540 0.533 0.1111 0.278 0.553 0.278 0.553 0.278 0.553 0.215 0.215 0.215 0.215 0.215 0.257 0.256 0.257 0.256 0.257 0.	2.060 1.202 1.586 1.285 1.285 1.285 1.285 1.397 1.394 1.087 1.394 1.125 1.285 1.285 1.285 1.285 1.397 1.394 1.125 1.285 1.285 1.285 1.285 1.295 1.394 1.297 1.394 1.285 1.285 1.285 1.285 1.295 1.297 1.297 1.297 1.297 1.297 1.297 1.294 1.285 1.285 1.285 1.285 1.285 1.285 1.285 1.285 1.285 1.295 1.	0.275 -1.485 -0.245 -1.486 -0.245 -1.644 -3.396 0.489 -3.192 -3.192 -3.192 -3.192 -3.192 -3.192 -3.192 -3.192 -3.192 -3.192 -3.192 -3.192 -3.192 -3.192 -3.192 -3.192 -3.2	0.783 0.135 0.135 0.135 0.135 0.135 0.135 0.135 0.135 0.100 0.001 0.021 0.001 0.021 0.123 0.199 0.103 0.123 0.199		Odds ratio a	2 5	*
Wu et al. 2008 Study name TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Hasherni et al. 2014 Hasheri et al. 2015 Shon et al. 2013 Hasheri et al. 2011 Wang et al. 2010 Miguer et al. 2008 Wu et al. 2008 Hwang et al. 2008 Study name TT vs. AA + AT Hu et al. 2015 Shon et al. 2019 Miguer et al. 2010 Miguer et al. 2010 Miguer et al. 2010 Miguer et al. 2010 Shon et al. 2011 Ansari et al. 2019 Miguer et al. 2010 Ansari et al. 2010	1.093 0.553 0.936 0.838 0.838 0.492 0.390 1.545 0.390 0.492 0.390 0.492 0.390 0.492 0.390 0.492 0.390 0.492 0.390 0.492 0.390 0.492 0.390 0.492 0.390 0.492 0.390 0.492 0.390 0.492 0.395 0.492 0.395	0.850 0.255 0.653 0.653 0.679 Statisti Lower Ilmit 0.326 0.010 0.310 0.321 0.021 0.679 0.606 0.481 0.721 0.679 0.606 0.481 0.721 0.630 0.679 0.630 0.421 0.658 0.679	2.060 1.202 1.202 1.586 1.386 1.586 1.685 1.685 1.695 1.695 1.695 1.695 1.695 1.697 1.287 1.297 1.283 1.087 1.125 1.125 1.125 1.125 1.125 1.283 1.092 1.125 1.283 1.097 1.125 1.283 1.095 1.283 1.097 1.125 1.283 1.095 1.283 1.097 1.125 1.283 1.095 1.383 1.885 1.	0.275 -1.485 -0.245 -1.684 z. Value z. Value -3.396 0.489 -3.396 0.489 -3.396 0.489 -3.392 -3.392 0.484 0.484 -1.331 -0.389 -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.284 x. -1.294 x. -1.284 x. -1	0.783 0.35 0.807 0.100 0.001 0.601 0.620 0.001 0.620 0.630 0.584 0.222 0.584 0.523 0.554 0.5550 0.555 0.5550		Odds ratio a	2 5	*
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2007 Vidyarani et al. 2006 TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Hashemi et al. 2011 Ansari et al. 2013 Ansari et al. 2008 Selvaraj et al. 2008 Wu et al. 2009 Wu et al. 2009 Wu et al. 2009 Wu et al. 2009 TT vs. AA + AT Hu et al. 2015 Shen et al. 2011 Masari et al. 2011	1.093 0.553 0.936 0.838 0.838 0.402 1.214 0.400 1.545 0.926 1.214 1.357 1.080 0.926 1.214 1.357 1.080 0.926 0.854 0.854 0.854 0.855 0.855 0.855 0.855 0.855 0.855 0.855 0.855 0.923 2.096 0.963	0.550 0.255 0.679 Statiati Lower limit 0.326 0.679 0.300 0.101 0.218 0.310 0.702 0.461 0.310 0.570 0.461 0.350 0.450 0.450 0.450 0.450 0.451 0.450 0.451 0.4	2.060 1.202 1.586 1.386 1.586 1.265 2.433 1.265 2.433 1.265 1.265 1.265 1.265 1.265 1.265 1.265 1.265 1.265 1.265 1.265 1.265 1.265 1.265 1.265 1.276 1.277 1.276 1.287 1.277 1.394 1.283 1.283 1.283 1.283 1.283 1.285 1.283 1.285 1.285 1.285 1.285 1.285 1.285 1.285 1.285 1.285 1.285 1.283 1.285 1.283 1.283 1.283 1.283 1.297 1.283 1.297 1.283 1.297 1.283 1.292 1.283 1.292 1.283 1.292 1.283 1.292 1.283 1.292 1.283 1.292 1.283 1.292 1.283 1.292 1.283 1.292 1.283 1.292 1.283 1.	0.275 -1.485 -0.245 -0.245 -1.644 z.Value -3.396 0.489 -3.396 0.489 -3.396 0.489 0.482 0.482 0.482 0.482 0.482 0.482 0.250 0.463 0.403 1.224 0.463 0.428 z.Value 0.428 0.4480000000000	0.783 0.135 0.807 0.100 0.100 0.100 0.101 0.625 0.630 0.523 0.199 p-Value 0.523 0.199		Odds ratio a	2 5	*
Wu et al. 2008 Study name TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Hashemi et al. 2013 Hashemi et al. 2014 Hashari et al. 2014 Ansari et al. 2014 Ansari et al. 2016 Shon et al. 2010 Ansari et al. 2010 Migg et al. 2000 Wu et al. 2006 Hwang et al. 2007 Vidyarani et al. 2006 Study name TT vs. AA + AT Hu et al. 2013 Ansari et al. 2010 Ansari et al. 2010 Ansar	1.093 0.553 0.936 0.838 0.438 0.432 0.492 1.244 1.357 0.926 1.244 1.357 0.926 0.926 0.926 0.926 0.926 0.854 0.854 0.6560 0.650 0.6553 0.923 2.0963 0.923	0.800 0.255 0.653 0.653 0.653 0.679 Statisti Lower limit 0.326 0.010 0.310 0.741 0.741 0.679 0.630 0.679 0.631 0.741 0.741 0.741 0.520 0.679 0.631 0.741 0.520 0.679 Statisti Uover limit 0.55 0.679	2.060 1.202 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 2.433 2.216 1.661 0.901 1.277 1.394 1.287 1.285 2.433 2.216 0.901 1.277 1.394 1.285 1.285 2.433 2.216 0.901 1.277 1.394 1.285 1.285 2.433 2.216 0.901 1.277 1.394 1.285 1.285 2.433 2.216 0.901 1.277 1.394 1.285 1.285 2.433 2.216 0.901 1.277 1.394 1.285 1.285 2.433 2.216 0.901 1.277 1.394 1.285 1.285 2.433 2.216 0.901 1.277 1.394 1.285 1.285 1.285 2.433 2.216 0.901 1.277 1.394 1.285 1.285 1.285 2.433 2.216 0.901 1.277 1.394 1.285 1.285 1.285 2.433 2.216 1.661 1.977 1.394 1.285 1.277 1.394 1.125 1.277 1.394 1.392 1.383 1.835 1.8388 1.8388 1.8388 1.8388 1.8388 1.8388 1.8388 1.8388 1	0.275 -1.485 -0.245 -1.486 xch study Z-Value -3.396 0.489 -3.392 -3.292 -3.	0.783 0.135 0.807 0.100 0.027 0.000 0.625 0.001 0.625 0.625 0.625 0.625 0.625 0.630 0.6830 0.584 0.727 0.727 0.727 0.727 0.727 0.7290 0.7290 0.72900000000000000000000000000000000000		Odds ratio a	2 5	*
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2007 Vidyarani et al. 2006 TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Hashemi et al. 2011 Ansari et al. 2013 Mang et al. 2010 Ansari et al. 2008 Wu et al. 2007 Vidyarani et al. 2008 Wu et al. 2015 Shen et al. 2011 Wang et al. 2011 Manger et al. 2010 Ansari et al. 2011 Manger et al. 2010 Manger et al. 2010 Ansari et al. 2011 Manger et al. 2010 Ansari et al. 2010 Manger et al. 2011 Manger et al. 2011 Ma	1.093 0.553 0.936 0.838 0.838 0.402 1.214 0.400 1.545 0.926 1.214 1.357 1.080 0.926 1.214 1.357 1.080 0.926 0.854 0.854 0.854 0.855 0.855 0.855 0.855 0.855 0.855 0.855 0.855 0.923 2.096 0.963	0.850 0.255 0.653 0.653 0.653 0.653 0.659 Statistik 0.326 0.326 0.326 0.320 0.320 0.320 0.320 0.320 0.310 0.501 0.520 0.341 0.278 0.340 0.313 1.112 0.279 0.340 0.313 1.112 0.279 0.340 0.313 0.31 0.127 0.314 0.310 0.314 0.315 0.314 0.315 0.315 0.315 0.275 0.429 0.310 0.275 0.429 0.310 0.275 0.429 0.420 0.255 0.429 0.420 0.255 0.429 0.420 0.255 0.429 0.420 0.255 0.4200 0.4200 0.4200 0.4200 0.4200 0.4200 0.4200 0.4200 0.4200 0.4200 0.4200 0.4200 0.4200 0.4200 0.4200 0.420000000000	2.060 1.202 1.586 1.386 1.586 1.685 1.265 1.265 1.265 1.265 1.265 1.265 1.265 1.265 1.265 1.265 1.265 1.265 1.265 1.277 1.277 1.277 1.277 1.277 1.278 1.283 1.285 1.285 1.283 1.285 1.285 1.285 1.285 1.283 1.285 1.285 1.283 1.285 1.283 1.285 1.283 1.285 1.283 1.285 1.283 1.285 1.283 1.285 1.283 1.285 1.283 1.283 1.285 1.283 1.283 1.283 1.288 1.288 1.285 1.283 1.285 1.283 1.288 1.	0.275 -1.485 -0.245 -0.245 -1.644 exh etudy Z.Value -3.396 -0.482 -3.396 -0.482 -0.482 -0.482 -0.482 -0.482 -0.250 -0.39 -1.284 exh etudy Z.Value -1.629 -1.284 exh etudy 0.348 exh etudy 0.348 -2.570 -0.482 -0.482 -0.483 z .282 -0.483 z .284 -0.483 z .284 -0.483 z .284 -0.483 z .284 -0.483 z .284 -0.483 z .284 -0.483 z .284 -0.483 z .284 -0.483 z .284 -0.483 z .295 -0.483 z .295 -0.483 z .295 -0.483 z .295 -0.483 z .295 -0.483 z .295 -0.483 z .284 -0.483 z .285 -0.483 z .285 -0.483 z .285 -0.483 z .285 -0.483 z .285 -0.483 z .285 -0.483 z .285 -0.483 z .284 -0.483 z .284 -0.483 z .284 -0.483 z .284 -0.483 z .295 -0.483 z .295 -0.484 z .295 -0.484 z .295 -0.483 z .295 -0.484 -0.484 z .295 -0.484 -0.483 z .295 -0.484 -0.494 -	0.783 0.135 0.807 0.100 0.100 0.100 0.100 0.021 0.021 0.021 0.021 0.222 0.727 0.212 0.183 0.199 0.183 0.199 0.199		Odds ratio a	2 5	*
Wu et al. 2008 Study name TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Hasherni et al. 2014 Hasheri et al. 2014 Hasheri et al. 2015 Shon et al. 2013 Manad et al. 2014 Ansari et al. 2014 Ansari et al. 2015 Shon et al. 2010 Miguet al. 2010 Miguet al. 2006 Hwang et al. 2007 Vidyarani et al. 2007 Vidyarani et al. 2007 Shon et al. 2015 Shon et al. 2013 Hasherni et al. 2011 Ansari et al. 2010 Ansari et al. 2010 Mang et al. 2010 Mang et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ansari et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ma	1.093 0.553 0.936 0.838 0.838 0.492 2.138 0.906 1.214 1.545 0.926 1.214 1.357 1.080 0.845 0.856 0.855	0.850 0.255 0.679 Statisti Lower limit 0.479 0.479 0.479 0.479 0.479 0.470 0.470 0.470 0.470 0.470 0.470 0.470 0.470 0.4500 0.450000000000	2 060 2 060 1.202 1.202 1.586 1.034 Upper limit 0.741 0.955 2.433 2.433 2.433 2.433 1.097 1.277 1.277 1.294 1.087 Upper limit 1.025 2.433 1.097 1.277 1.273 1.293 1.027 1.293	0.275 -1.495 -0.245 -1.644 ech study Z-Value -3.396 0.489 -3.192 1.614 -3.396 0.489 -3.192 1.614 -0.482 0.482 0.482 0.482 0.482 0.482 0.482 0.482 0.483 0.2570 0.236 0.433 0.2570 0.236 0.432 0.245 0.432 0.245 0.432 0.245 0.482 0.482 0.432 0.2570 0.236 0.432 0.2570 0.236 0.432 0.2570 0.236 0.432 0.432 0.457 0.2570 0.22200 0.22200 0.22200 0.22200 0.22200 0.22200 0.22200 0.22200 0.22200 0.22200 0.22200 0.22200 0.22200 0.22200 0.2200000000	0.783 0.135 0.807 0.100 0.135 0.807 0.100 0.625 0.625 0.625 0.625 0.625 0.625 0.625 0.625 0.630 0.683 0.523 0.727 0.727 0.727 0.727 0.729 0.724 0.729 0.724 0.721 0.729 0.221 0.022 0.221 0.022 0.224 0.022 0.224 0.022 0.224 0.022 0.224 0.022 0.025 0.025 0.024 0.022 0.024 0.022 0.024 0.022 0.024 0.024 0.024 0.024 0.024 0.024 0.024 0.024 0.024 0.025 0.000 0.025		Odds ratio a	2 5	*
Wu et al. 2008 Hwang et al. 2007 Vidyarani et al. 2007 Vidyarani et al. 2006 TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Hashemi et al. 2011 Ansari et al. 2013 Mang et al. 2010 Ansari et al. 2008 Wu et al. 2007 Vidyarani et al. 2008 Wu et al. 2015 Shen et al. 2011 Wang et al. 2011 Manger et al. 2010 Ansari et al. 2011 Manger et al. 2010 Ansari et al. 2011 Manger et al. 2010 Manger et al. 2011 Manger et al. 2011 Ma	1.093 0.553 0.936 0.838 0.838 0.936 0.936 0.936 0.936 1.214 1.357 1.080 0.845 1.214 1.357 1.080 0.845 0.854 0.854 0.854 0.855 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.855 0.854 0.855 0.855 0.854 0.855 0.855 0.854 0.855 0.855 0.854 0.855 0.855 0.855 0.855 0.855 0.926 0.855 0.855 0.855 0.926 0.855 0.926 0.855 0.855 0.855 0.855 0.855 0.926 0.855 0.855 0.855 0.926 0.855 0.926 0.855 0.855 0.855 0.926 0.855	0.850 0.255 0.653 0.653 0.653 0.653 0.659 Statisti 0.255 0.659 Statisti 0.255 0.257 0.	2 060 1.202 1.506 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 2.618 0.995 2.618 2.216 1.661 0.901 1.265 2.216 1.661 0.995 1.265 2.433 1.686 1.687 1.277 1.277 1.394 1.283 3.237 1.283 3.335 1.283 3.335 1.283 3.335 1.283 3.335 1.283 3.335 1.283 1.285 1.285 1.285 1.285 1.285 1.285 1.283 1.285 1.285 1.285 1.283 1.285 1.283 1.285 1.283 1.285 1.283 1.283 1.285 1.283 1.283 1.283 1.283 1.285 1.283 1.285 1.283 1.283 1.283 1.283 1.284 1.285 1.283 1.283 1.283 1.284 1.285 1.283 1.283 1.284 1.285 1.283 1.284 1.285 1.283 1.284 1.285 1.283 1.284 1.283 1.284 1.285 1.284 1.285 1.284 1.284 1.285 1.284 1.285 1.284 1.285 1.284 1.285 1.284 1.285 1.284 1.285 1.284 1.285 1.284 1.285 1.284 1.285 1.	0.275 -1.495 -0.245 -0.245 -0.245 Z-Value Z-Value -3.396 -0.489 -3.192 -1.614 -0.482 -0.482 -0.482 -0.482 -0.482 -0.2570 -0.348 -2.570 -0.348 -2.570 -1.284 Z-Value -1.224 -1.244 -1.144	0.783 0.135 0.807 0.100 0.015 0.807 0.010 0.825 0.655 0.6550 0.6550 0.6550000000000		Odds ratio a	2 5	*
Wu et al. 2008 Study name TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Hasherni et al. 2014 Hasheri et al. 2014 Hasheri et al. 2015 Shon et al. 2013 Manad et al. 2014 Ansari et al. 2014 Ansari et al. 2015 Shon et al. 2010 Miguet al. 2010 Miguet al. 2006 Hwang et al. 2007 Vidyarani et al. 2007 Vidyarani et al. 2007 Shon et al. 2015 Shon et al. 2013 Hasherni et al. 2011 Ansari et al. 2010 Ansari et al. 2010 Mang et al. 2010 Mang et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ansari et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ma	1.093 0.553 0.936 0.838 0.838 0.492 2.138 0.906 1.214 1.545 0.926 1.214 1.357 1.080 0.845 0.856 0.855	0.850 0.255 0.679 Statisti Lower limit 0.479 0.479 0.479 0.479 0.479 0.470 0.470 0.470 0.470 0.470 0.470 0.470 0.470 0.4500 0.450000000000	2 060 2 060 1.202 1.202 1.586 1.034 Upper limit 0.741 0.955 2.433 2.433 2.433 2.433 1.097 1.277 1.277 1.294 1.087 Upper limit 1.025 2.433 1.097 1.277 1.273 1.293 1.027 1.293	0.275 -1.495 -0.245 -1.644 ech study Z-Value -3.396 0.489 -3.192 1.614 -3.396 0.489 -3.192 1.614 -0.482 0.482 0.482 0.482 0.482 0.482 0.482 0.482 0.483 0.2570 0.236 0.433 0.2570 0.236 0.432 0.245 0.432 0.245 0.432 0.245 0.482 0.482 0.432 0.2570 0.236 0.432 0.2570 0.236 0.432 0.2570 0.236 0.432 0.432 0.457 0.2570 0.22200 0.22200 0.22200 0.22200 0.22200 0.22200 0.22200 0.22200 0.22200 0.22200 0.22200 0.22200 0.22200 0.22200 0.2200000000	0.783 0.135 0.807 0.100 0.135 0.807 0.100 0.625 0.625 0.625 0.625 0.625 0.625 0.625 0.625 0.630 0.683 0.523 0.727 0.727 0.727 0.727 0.729 0.724 0.729 0.724 0.721 0.729 0.221 0.022 0.221 0.022 0.224 0.022 0.224 0.022 0.224 0.022 0.224 0.022 0.025 0.025 0.024 0.022 0.024 0.022 0.024 0.022 0.024 0.024 0.024 0.024 0.024 0.024 0.024 0.024 0.024 0.025 0.000 0.025	0.1	Odds ratio a	and 95% Cl	10
Wu et al. 2008 Study name TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Hasherni et al. 2014 Hasheri et al. 2014 Hasheri et al. 2015 Shon et al. 2013 Manad et al. 2014 Ansari et al. 2014 Ansari et al. 2015 Shon et al. 2010 Miguet al. 2010 Miguet al. 2006 Hwang et al. 2007 Vidyarani et al. 2007 Vidyarani et al. 2007 Shon et al. 2015 Shon et al. 2013 Hasherni et al. 2011 Ansari et al. 2010 Ansari et al. 2010 Mang et al. 2010 Mang et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ansari et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ma	1.093 0.553 0.936 0.838 0.838 0.936 0.838 0.900 1.214 0.926 1.214 1.357 1.080 0.845 1.357 1.080 0.845 0.854 0.854 0.854 0.855 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.855 0.854 0.855 0.855 0.854 0.855 0.855 0.854 0.855 0.855 0.855 0.855 0.855 0.855 0.855 0.855 0.926 0.855 0.855 0.855 0.926 0.855 0.855 0.855 0.855 0.855 0.855 0.855 0.926 0.855 0.855 0.855 0.926 0.855 0.855 0.855 0.855 0.926 0.855	0.850 0.255 0.653 0.653 0.653 0.653 0.659 Statisti 0.255 0.659 Statisti 0.255 0.257 0.	2 060 1.202 1.506 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 2.618 0.995 2.618 2.618 0.995 2.618 1.265 2.433 1.265 2.436 1.265 1.265 2.433 1.265 2.436 1.265 1.265 2.433 1.265 2.436 1.265 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.436 1.265 1.265 2.435 1.265 2.436 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.277 1.277 1.277 1.277 1.277 1.273 1.283 3.235 3.235 1.283 3.235 1.283 3.237 1.275 1.283 3.235 1.283 3.237 1.275 1.283 3.237 1.227 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.283 3.235 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 1.283 3.237 1.283 1.284 1.285 1.283 1.283 1.283 1.283 1.284 1.283 1.283 1.283 1.283 1.284 1.283 1.283 1.283 1.283 1.284 1.283 1.284 1.283 1.284 1.284 1.283 1.284 1.	0.275 -1.495 -0.245 -0.245 -0.245 Z-Value Z-Value -3.396 -0.489 -3.192 -1.614 -0.482 -0.482 -0.482 -0.482 -0.482 -0.2570 -0.348 -2.570 -0.348 -2.570 -1.284 Z-Value -1.224 -1.244 -1.144	0.783 0.135 0.807 0.100 0.015 0.807 0.010 0.825 0.655 0.6550 0.6550 0.6550000000000		Odds ratio a	2 5	*
Wu et al. 2008 Study name TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Hasherni et al. 2014 Hasheri et al. 2014 Hasheri et al. 2015 Shon et al. 2013 Manad et al. 2014 Ansari et al. 2014 Ansari et al. 2015 Shon et al. 2010 Miguet al. 2010 Miguet al. 2006 Hwang et al. 2007 Vidyarani et al. 2007 Vidyarani et al. 2007 Shon et al. 2015 Shon et al. 2013 Hasherni et al. 2011 Ansari et al. 2010 Ansari et al. 2010 Mang et al. 2010 Mang et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ansari et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ma	1.093 0.553 0.936 0.838 0.838 0.936 0.838 0.900 1.214 0.926 1.214 1.357 1.080 0.845 1.357 1.080 0.845 0.854 0.854 0.854 0.855 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.855 0.854 0.855 0.855 0.854 0.855 0.855 0.854 0.855 0.855 0.855 0.855 0.855 0.855 0.855 0.855 0.926 0.855 0.855 0.855 0.926 0.855 0.855 0.855 0.855 0.855 0.855 0.855 0.926 0.855 0.855 0.855 0.926 0.855 0.855 0.855 0.855 0.926 0.855	0.850 0.255 0.653 0.653 0.653 0.653 0.659 Statisti 0.255 0.659 Statisti 0.255 0.257 0.	2 060 1.202 1.506 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 2.618 0.995 2.618 2.618 0.995 2.618 1.265 2.433 1.265 2.436 1.265 1.265 2.433 1.265 2.436 1.265 1.265 2.433 1.265 2.436 1.265 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.436 1.265 1.265 2.435 1.265 2.436 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.277 1.277 1.277 1.277 1.277 1.273 1.283 3.235 3.235 1.283 3.235 1.283 3.237 1.275 1.283 3.235 1.283 3.237 1.275 1.283 3.237 1.227 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.283 3.235 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 1.283 3.237 1.283 1.284 1.285 1.283 1.283 1.283 1.283 1.284 1.283 1.283 1.283 1.283 1.284 1.283 1.283 1.283 1.283 1.284 1.283 1.284 1.283 1.284 1.284 1.283 1.284 1.	0.275 -1.495 -0.245 -0.245 -0.245 Z-Value Z-Value -3.396 -0.489 -3.192 -0.489 -0.489 -0.489 -0.489 -0.482 -0.482 -0.2570 -0.348 -2.570 -0.348 -2.570 -1.284 Z-Value -1.224 -1.244 -1.144	0.783 0.135 0.807 0.100 0.015 0.807 0.010 0.825 0.655 0.6550 0.6550 0.6550000000000	0.1	Odds ratio a	and 95% Cl	10
Wu et al. 2008 Study name TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Hasherni et al. 2014 Hasheri et al. 2014 Hasheri et al. 2015 Shon et al. 2013 Manad et al. 2014 Ansari et al. 2014 Ansari et al. 2015 Shon et al. 2010 Miguet al. 2010 Miguet al. 2006 Hwang et al. 2007 Vidyarani et al. 2007 Vidyarani et al. 2007 Shon et al. 2015 Shon et al. 2013 Hasherni et al. 2011 Ansari et al. 2010 Ansari et al. 2010 Mang et al. 2010 Mang et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ansari et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ma	1.093 0.553 0.936 0.838 0.838 0.936 0.838 0.900 1.214 0.926 1.214 1.357 1.080 0.845 1.357 1.080 0.845 0.854 0.854 0.854 0.855 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.855 0.854 0.855 0.855 0.854 0.855 0.855 0.854 0.855 0.855 0.855 0.855 0.855 0.855 0.855 0.855 0.926 0.855 0.855 0.855 0.926 0.855 0.855 0.855 0.855 0.855 0.855 0.855 0.926 0.855 0.855 0.855 0.926 0.855 0.855 0.855 0.855 0.926 0.855	0.850 0.255 0.653 0.653 0.653 0.653 0.659 Statisti 0.255 0.659 Statisti 0.255 0.257 0.	2 060 1.202 1.506 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 2.618 0.995 2.618 2.618 0.995 2.618 1.265 2.433 1.265 2.436 1.265 1.265 2.433 1.265 2.436 1.265 1.265 2.433 1.265 2.436 1.265 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.436 1.265 1.265 2.435 1.265 2.436 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.277 1.277 1.277 1.277 1.277 1.273 1.283 3.235 3.235 1.283 3.235 1.283 3.237 1.275 1.283 3.235 1.283 3.237 1.275 1.283 3.237 1.227 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.283 3.235 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 1.283 3.237 1.283 1.284 1.285 1.283 1.283 1.283 1.283 1.284 1.283 1.283 1.283 1.283 1.284 1.283 1.283 1.283 1.283 1.284 1.283 1.284 1.283 1.284 1.284 1.283 1.284 1.	0.275 -1.495 -0.245 -0.245 -0.245 Z-Value Z-Value -3.396 -0.489 -3.192 -0.489 -0.489 -0.489 -0.489 -0.482 -0.482 -0.2570 -0.348 -2.570 -0.348 -2.570 -1.284 Z-Value -1.224 -1.244 -1.144	0.783 0.135 0.807 0.100 0.015 0.807 0.010 0.825 0.655 0.6550 0.6550 0.6550000000000	0.1	Odds ratio a	and 95% Cl	10
Wu et al. 2008 Study name TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Hasherni et al. 2014 Hasheri et al. 2014 Hasheri et al. 2015 Shon et al. 2013 Manad et al. 2014 Ansari et al. 2014 Ansari et al. 2015 Shon et al. 2010 Miguet al. 2010 Miguet al. 2006 Hwang et al. 2007 Vidyarani et al. 2007 Vidyarani et al. 2007 Shon et al. 2015 Shon et al. 2013 Hasherni et al. 2011 Ansari et al. 2010 Ansari et al. 2010 Mang et al. 2010 Mang et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ansari et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ma	1.093 0.553 0.936 0.838 0.838 0.936 0.838 0.900 1.214 0.926 1.214 1.357 1.080 0.845 1.357 1.080 0.845 0.854 0.854 0.854 0.855 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.855 0.854 0.855 0.855 0.854 0.855 0.855 0.854 0.855 0.855 0.855 0.855 0.855 0.855 0.855 0.855 0.926 0.855 0.855 0.855 0.926 0.855 0.855 0.855 0.855 0.855 0.855 0.855 0.926 0.855 0.855 0.855 0.926 0.855 0.855 0.855 0.855 0.926 0.855	0.850 0.255 0.653 0.653 0.653 0.653 0.659 Statisti 0.255 0.659 Statisti 0.255 0.257 0.	2 060 1.202 1.506 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 2.618 0.995 2.618 2.618 0.995 2.618 1.265 2.433 1.265 2.436 1.265 1.265 2.433 1.265 2.436 1.265 1.265 2.433 1.265 2.436 1.265 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.436 1.265 1.265 2.435 1.265 2.436 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.277 1.277 1.277 1.277 1.277 1.273 1.283 3.235 3.235 1.283 3.235 1.283 3.237 1.275 1.283 3.235 1.283 3.237 1.275 1.283 3.237 1.227 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.283 3.235 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 1.283 3.237 1.283 1.284 1.285 1.283 1.283 1.283 1.283 1.284 1.283 1.283 1.283 1.283 1.284 1.283 1.283 1.283 1.283 1.284 1.283 1.284 1.283 1.284 1.284 1.283 1.284 1.	0.275 -1.495 -0.245 -0.245 -0.245 Z-Value Z-Value -3.396 -0.489 -3.192 -0.489 -0.489 -0.489 -0.489 -0.482 -0.482 -0.2570 -0.348 -2.570 -0.348 -2.570 -1.284 Z-Value -1.224 -1.244 -1.144	0.783 0.135 0.807 0.100 0.015 0.807 0.010 0.825 0.655 0.6550 0.6550 0.6550000000000	0.1	Odds ratio a	and 95% Cl	10
Wu et al. 2008 Study name TT + AT vs. AA Hu et al. 2015 Shon et al. 2013 Hasherni et al. 2014 Hasheri et al. 2014 Hasheri et al. 2015 Shon et al. 2013 Manad et al. 2014 Ansari et al. 2014 Ansari et al. 2015 Shon et al. 2010 Miguet al. 2010 Miguet al. 2006 Hwang et al. 2007 Vidyarani et al. 2007 Vidyarani et al. 2007 Shon et al. 2015 Shon et al. 2013 Hasherni et al. 2011 Ansari et al. 2010 Ansari et al. 2010 Mang et al. 2010 Mang et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ansari et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ansari et al. 2010 Mang et al. 2010 Ma	1.093 0.553 0.936 0.838 0.838 0.936 0.838 0.900 1.214 0.926 1.214 1.357 1.080 0.845 1.357 1.080 0.845 0.854 0.854 0.854 0.855 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.928 0.854 0.855 0.854 0.855 0.855 0.854 0.855 0.855 0.854 0.855 0.855 0.855 0.855 0.855 0.855 0.855 0.855 0.926 0.855 0.855 0.855 0.926 0.855 0.855 0.855 0.855 0.855 0.855 0.855 0.926 0.855 0.855 0.855 0.926 0.855 0.855 0.855 0.855 0.926 0.855	0.850 0.255 0.653 0.653 0.653 0.653 0.659 Statisti 0.255 0.659 Statisti 0.255 0.257 0.	2 060 1.202 1.506 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 1.586 2.618 0.995 2.618 2.618 0.995 2.618 1.265 2.433 1.265 2.436 1.265 1.265 2.433 1.265 2.436 1.265 1.265 2.433 1.265 2.436 1.265 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.436 1.265 1.265 2.435 1.265 2.436 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.265 2.435 1.277 1.277 1.277 1.277 1.277 1.273 1.283 3.235 3.235 1.283 3.235 1.283 3.237 1.275 1.283 3.235 1.283 3.237 1.275 1.283 3.237 1.227 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.277 1.283 3.235 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 3.237 1.283 1.283 3.237 1.283 1.284 1.285 1.283 1.283 1.283 1.283 1.284 1.283 1.283 1.283 1.283 1.284 1.283 1.283 1.283 1.283 1.284 1.283 1.284 1.283 1.284 1.284 1.283 1.284 1.	0.275 -1.495 -0.245 -0.245 -0.245 Z-Value Z-Value -3.396 -0.489 -3.192 -0.489 -0.489 -0.489 -0.489 -0.482 -0.482 -0.2570 -0.348 -2.570 -0.348 -2.570 -1.284 Z-Value -1.224 -1.244 -1.144	0.783 0.135 0.807 0.100 0.015 0.807 0.010 0.825 0.655 0.6550 0.6550 0.6550000000000	0.1	Odds ratio a	and 95% Cl	10

Study name

T vs. A

Statistics for each study

Lower

Upper limit Z-Value p-Value

Figure 4. Forest plots of ORs with 95% CI of PTB risk associated with the IFN- γ +874 A>T gene polymorphism in the Asian population (allelic contract (T vs. A), homozygous (TT vs. AA), heterozygous (AT vs. AA), dominant (TT+AT vs. AT), recessive (TT vs. AA+AT) genetic models). The black square represents the value of OR, and the size of the square indicates the inverse proportion relative to its variance. The horizontal line is the 95% CI of OR

authenticity of our results. In addition, all the included studies were of good to moderate quality, fulfilling the pre-set criteria for study inclusion as tested by the NOS quality assessment scale.




Figure 5. Forest plots of ORs with 95% CI of PTB risk associated with the IFN- γ +874 A>T gene polymorphism in the Caucasian population (allelic contract (T vs. A), homozygous (TT vs. AA), heterozygous (AT vs. AA), dominant (TT+AT vs. AT), recessive (TT vs. AA+AT) genetic models). The black square represents the value of OR, and the size of the square indicates the inverse proportion relative to its variance. The horizontal line is the 95% CI of OR

In conclusion, that *IFN-* γ +874 A>T gene polymorphism is significantly associated with decreased risk of PTB, showing a protective effect in the overall and in the Caucasian population. Whereas, +874 A>T polymorphism of *IFN-* γ gene is not associated with increased/decreased risk of PTB in the Asian population. As the immune response in PTB infection is polygenic in nature, further larger clinical and laboratory studies are warranted to improve our understanding of the mechanism of the cytokine gene in such a complex disease. This will help in the identification of host immunogenetic factors responsible for PTB susceptibility, which may help in the controlling of this infectious disease.

Comparisons	Egge	r's regression analy	/sis	He	s	Model used	
	Intercept	95% Confidence Interval	e <i>P</i> -value <i>Q</i> -value		Pheterogeneity	l² (%)	for the meta-analysis
T vs. A	-3.04	-10.89 to 4.81	0.305	9.415	0.052	57.51	Fixed
TT vs. AA	-2.83	-8.13 to 2.45	0.186	7.332	0.119	45.44	Fixed
AT vs. AA	1.33	-7.88 to 10.55	0.675	8.721	0.068	54.13	Fixed
TT+AT vs. AA	0.14	-9.36 to 9.65	0.963	8.842	0.065	54.76	Fixed
TT vs. AA+AT	-3.63	-6.52 to -0.75	0.027	7.780	0.100	48.58	Fixed

Table VI. Statistics to test publication bias and heterogeneity in the meta-analysis: Caucasian population

Acknowledgments

The authors are thankful to the Deanship Scientific Research, Jazan University, Jazan-45142, Saudi Arabia for providing the necessary dry lab facilities for this research study.

Mohammed Y. Areeshi and Raju K. Mandal contributed equally to this work.

Conflict of interest

The authors declare no conflict of interest.

References

- 1. World Health Organization, Global Tuberculosis Report, 2015. Availbale at: http://apps.who.int/iris/bitstream/ 10665/191102/1/9789241565059_eng.pdf?ua=1.
- Schluger NW. Recent advances in our understanding of human host responses to tuberculosis. Respir Res 2001; 2: 157-63.
- 3. Bellamy R. Susceptibility to Mycobacterial infections: the importance of host genetics. Genes Immun 2003; 4: 4-11.
- 4. Kiliszek M, Kozluk E, Franaszczyk M, et al. The 4q25, 1q21, and 16q22 polymorphisms and recurrence of atrial fibrillation after pulmonary vein isolation. Arch Med Sci 2016; 12: 38-44.
- Mlak R, Homa-Mlak I, Powrózek T, et al. Impact of I/D polymorphism of ACE gene on risk of development and course of chronic obstructive pulmonary disease. Arch Med Sci 2016; 12: 279-87.
- Ozdemirkiran FG, Nalbantoglu S, Gokgoz Z, et al. FAS/ FASL gene polymorphisms in Turkish patients with chronic myeloproliferative disorders. Arch Med Sci 2017; 13: 426-32.
- 7. Ferraz JC, Melo FB, Albuquerque MF, Montes C, Abath FG. Immune factors and immunoregulation in tuberculosis. Braz J Med Biol Res 2006; 39: 1387-97.
- Condos R, Rom WN, Liu YM, Schluger NW. Local immune responses correlate with presentation and outcome in tuberculosis. Am J Respir Crit Care Med 1998; 157: 729-35.
- 9. Ottenhoff TH, Kumararatne D, Casanova JL. Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria. Immunol Today 1998; 19: 491-4.
- Lopez-Maderuelo D, Arnalich F, Serantes R, et al. Interferon-gamma and interleukin-10 gene polymorphisms in pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 167: 970-5.
- 11. Pacheco AG, Cardoso CC, Moraes MO. IFNG +874 T/A, IL10-1082 G/A and TNF -308G/A polymorphisms in as-

sociation with tuberculosis susceptibility: a meta-analysis study. Hum Genet 2008; 123: 477-84.

- 12. Hu Y, Wu L, Li D, Zhao Q, Jiang W, Xu B. Association between cytokine gene polymorphisms and tuberculosis in a Chinese population in Shanghai: a case-control study. BMC Immunol 2015; 16: 8.
- 13. Mabunda N, Alvarado-Arnez LE, Vubil A, et al. Gene polymorphisms in patients with pulmonary tuberculosis from Mozambique. Mol Biol Rep 2015; 42: 71-6.
- 14. Shen C, Jiao WW, Feng WX, et al. IFNG polymorphisms are associated with tuberculosis in Han Chinese pediatric female population. Mol Biol Rep 2013; 40: 5477-82.
- Selma BW, Harizi H, Bougmiza I, et al. Interferon gamma +874 T/A polymorphism is associated with susceptibility to active pulmonary tuberculosis development in Tunisian patients. DNA Cell Biol 2011; 30: 379-87.
- 16. Hashemi M, Sharifi-Mood B, Nezamdoost M, et al. Functional polymorphism of interferon-γ (IFN-γ) gene +874T/A polymorphism is associated with pulmonary tuberculosis in Zahedan, Southeast Iran. Prague Med Rep 2011; 112: 38-43.
- 17. Ansari A, Hasan Z, Dawood G, Hussain R. Differential combination of cytokine and interferon-γ +874 T/A polymorphisms determines disease severity in pulmonary tuberculosis. PLoS One 2011; 6: e27848.
- Vallinoto AC, Graça ES, Araújo MS, et al. IFNG +874T/A polymorphism and cytokine plasma levels are associated with susceptibility to Mycobacterium tuberculosis infection and clinical manifestation of tuberculosis. Hum Immunol 2010; 71: 692-6.
- Wang J, Tang S, Shen H. Association of genetic polymorphisms in the IL12-IFNG pathway with susceptibility to and prognosis of pulmonary tuberculosis in a Chinese population. Eur J Clin Microbiol Infect Dis 2010; 29: 1291-5.
- 20. Anand PS, Harishankar M, Selvaraj P. Interferon gamma gene +874 A/T polymorphism and intracellular interferon gamma expression in pulmonary tuberculosis. Cytokine 2010; 49: 130-3.
- 21. Ansari A, Talat N, Jamil B, et al. Cytokine gene polymorphisms across tuberculosis clinical spectrum in Pakistani patients. PLoS One 2009; 4: e4778.
- 22. Selvaraj P, Alagarasu K, Harishankar M, Vidyarani M, Nisha Rajeswari D, Narayanan PR. Cytokine gene polymorphisms and cytokine levels in pulmonary tuberculosis. Cytokine 2008; 43: 26-33.
- 23. Ding S, Li L, Zhu X. Polymorphism of the interferon-gamma gene and risk of tuberculosis in a southeastern Chinese population. Hum Immunol 2008; 69: 129-33.
- 24. Wu F, Qu Y, Tang Y, Cao D, Sun P, Xia Z. Lack of association between cytokine gene polymorphisms and silicosis and pulmonary tuberculosis in Chinese iron miners. J Occup Health 2008; 50: 445-54.

- 25. Hwang JH, Kim EJ, Kim SY, et al. Polymorphisms of interferon-gamma and interferon-gamma receptor 1 genes and pulmonary tuberculosis in Koreans. Respirology 2007; 12: 906-10.
- Moran A, Ma X, Reich RA, Graviss EA. No association between the +874 T/A single nucleotide polymorphism in the IFN-gamma gene and susceptibility to TB. Int J Tuberc Lung Dis 2007; 11: 113-5.
- 27. Sallakci N, Coskun M, Berber Z, et al. Interferon-gamma gene+874 T-A polymorphism is associated with tuberculosis and gamma interferon response. Tuberculosis (Edinb) 2007; 87: 225-30.
- Cooke GS, Campbell SJ, Sillah J, et al. Polymorphism within the interferon-gamma/receptor complex is associated with pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 339-43.
- 29. Vidyarani M, Selvaraj P, Prabhu Anand S, Jawahar MS, Adhilakshmi AR, Narayanan PR. Interferon gamma (IFN gamma) & interleukin-4 (IL-4) gene variants & cytokine levels in pulmonary tuberculosis. Indian J Med Res 2006; 124: 403-10.
- 30. Etokebe GE, Bulat-Kardum L, Johansen MS, et al. Interferon-gamma gene (T874A and G2109A) polymorphisms are associated with microscopy-positive tuberculosis. Scand J Immunol 2006; 63: 136-41.
- López-Maderuelo D, Arnalich F, Serantes R, et al. Interferon-gamma and interleukin-10 gene polymorphisms in pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 167: 970-5.
- 32. Lio D, Marino V, Serauto A, et al. Genotype frequencies of the +874T-->A single nucleotide polymorphism in the first intron of the interferon-gamma gene in a sample of Sicilian patients affected by tuberculosis. Eur J Immunogenet 2002; 29: 371-4.
- 33. Sheng WY, Yong Z, Yun Z, Hong H, Hai LL. Toll-like receptor 4 gene polymorphisms and susceptibility to colorectal cancer: a meta-analysis and review. Arch Med Sci 2015; 11: 699-707.
- 34. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-5.
- 35. Hu P, Huang MY, Hu XY, et al. Meta-analysis of C242T polymorphism in CYBA genes: risk of acute coronary syndrome is lower in Asians but not in Caucasians. J Zhejiang Univ Sci B 2015; 16: 370-9.
- Wu R, Li B. A multiplicative-epistatic model for analyzing interspecific differences in outcrossing species. Biometrics 1999; 55: 355-65.
- 37. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-48.
- 38. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 3: 177-88.
- Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
- 40. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
- 41. Egger M, Davey Smith G, Schneider M, et al. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
- 42. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001; 19: 93-129.
- Moller M, de Wit E, Hoal EG. Past, present and future directions in human genetic susceptibility to tuberculosis. FEMS Immunol Med Microbiol 2010; 58: 3-26.

- 44. Rockett KA, Brookes R, Udalova I, et al. 1,25- Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line. Infect Immun 1998; 66: 5314-21.
- Ioannidis JP, Boffetta P, Little J, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol 2008; 37: 120-32.
- Racial differences in susceptibility to infection by Mycobacterium tuberculosis. N Engl J Med 1990; 322: 422-7.
- Bellamy R. Genome-wide approaches to identifying genetic factors in host susceptibility to tuberculosis. Microbes Infect 2006; 8: 1119-23.
- Cervino AC, Lakiss S, Sow O, et al. Fine mapping of a putative tuberculosis-susceptibility locus on chromosome 15q11-13 in African families. Hum Mol Genet 2002; 11: 1599-1603.
- 49. Petri WA, Beth D, Patrick K, Haque R, Duggal P. Genes influencing susceptibility to infection. J Infect Dis 2008; 197: 4-6.